Monkeypox virus OPG153 globular domain vaccine

Engineering the monkeypox virus OPG153 protein globular domain with specific substitutions and fusions addresses the limitations of current MPXV vaccines by enhancing immunogenicity and durability, achieving broad neutralization and cost-effective protection against MPXV.

WO2026236648A1PCT designated stage Publication Date: 2026-11-12BOARD OF RGT THE UNIV OF TEXAS SYST +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027339
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-09-17
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current vaccines and therapeutics for monkeypox virus (MPXV) exhibit limited immunogenicity, durability, and clinical efficacy, particularly in smallpox vaccine-naive individuals and immunocompromised individuals, necessitating the development of next-generation vaccines and therapeutics with enhanced immunogenicity and clinical efficacy.

Method used

Engineering the monkeypox virus OPG153 protein globular domain with specific substitutions and fusions to enhance solubility, stability, and immunogenicity, and conjugating it with heterologous polypeptides or delivering it via nucleic acid molecules to elicit broad neutralizing antibody responses.

Benefits of technology

The engineered OPG153 protein domains induce significantly higher neutralizing antibody titers and provide cross-neutralization against both MV and EV forms of MPXV, offering improved protection and reduced manufacturing costs, potentially benefiting low- and middle-income countries.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000013_0001_TABLE
    Figure IMGF000013_0001_TABLE
  • Figure IMGF000014_0001_TABLE
    Figure IMGF000014_0001_TABLE
  • Figure IMGF000015_0001_TABLE
    Figure IMGF000015_0001_TABLE
Patent Text Reader

Abstract

Provided herein are engineered OPG153 globular domain-containing proteins that exhibit enhanced stability and / or antigenicity. Methods are also provided for use of the engineered OPG153 globular domain-containing proteins as diagnostics, in screening platforms, and / or in vaccine compositions.
Need to check novelty before this filing date? Find Prior Art

Description

DESCRIPTIONMONKEYPOX VIRUS OPG153 GLOBULAR DOMAIN VACCINEREFERENCE TO RELATED APPLICATIONS

[0001] The present application claims the priority benefit of United States provisional application number 63 / 883,274, filed September 17, 2025, and United States provisional application number 63 / 802,899, filed May 9, 2025, the entire contents of which are incorporated herein by reference.REFERENCE TO A SEQUENCE LISTING

[0002] This application contains a sequence listing XML, which has been submitted electronically and is hereby incorporated by reference in its entirety. Said sequence listing XML, created on May 8, 2026, is named UTFBP1397WO.xml and is 33,944 bytes in size.BACKGROUND1. Field

[0003] The present disclosure relates generally to the fields of medicine, virology, immunology, and protein engineering. More particularly, it concerns engineered monkeypox virus or vaccinia virus OPG153 protein polypeptides, immunogenic compositions of monkeypox virus OPG153, and methods of using immunogenic compositions of monkeypox virus or vaccinia virus OPG153.2. Description of Related Art

[0004] For more than five decades, monkeypox virus (MPXV) was considered a geographically restricted zoonotic pathogen, primarily affecting regions in Central (Clade I) and West (Clade II) Africa (MacNeill, et al., 2022). However, beginning in 2022, MPXV exhibited unprecedented global human-to-human spread, predominated by the circulation of MPXV Clade lib (MPXV-IIb) (Moss, et al., 2025; Beiras, et al., 2025). A subsequent outbreak in 2024, distinguished by the emergence of MPXV Clade lb (MPXV-Ib), has further underscored the threat posed by this vims and prompted the World Health Organization (WHO) to declare a Public Health Emergency of International Concern (Moss, et al., 2025; WHO, 2024). From January 2022 through March 2025, the WHO reported 137,892 mpox cases globally and 317 deaths in 132 countries (WHO, 2025). As of April 2025, there have been over 14922-1531-8179, v. 130,000 estimated cases due to MPXV-Ib globally (WHO, 2025). The modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine — approved for emergency use during these outbreaks — demonstrated high real-world effectiveness (Mucker, et al., 2024; Rosenberg, et al., 2023; Nicholas, et al., 2023; Zaeck, et al., 2023; Lin, et al., 2024; Dalton, et al., 2023). In smallpox vaccine-naive individuals, however, a two-dose MVA-BN regimen induced modest and short-lived neutralizing antibody responses against MPXV (Zaeck, et al., 2023; Grabenstein, et al., 2024; Phipps, et al., 2025). While the vaccine is generally well-tolerated, rare but severe adverse effects have been reported in immunocompromised individuals (Raccagni, et al., 2023), warranting further clinical monitoring. Similarly, tecovirimat, the only approved antiviral for treating MPXV infection, did not reduce the duration of pox lesions among children and adults with MPXV-I infection (Ali, et al., 2025). While current medical countermeasures have been instrumental in controlling recent mpox outbreaks, the development of next-generation vaccines and therapeutics with enhanced immunogenicity, durability, and clinical efficacy remains an unmet priority for global health.

[0005] The studies described herein led to the identification of OPG153 as a major target of orthopoxvirus broadly neutralizing antibodies. OPG 153 -targeting antibodies show high neutralization potency, bind at least three different regions of the OPG153 globular domain, and appear to neutralize both the MV and EV forms of the virus, although the dose required to neutralize EV was much higher than that needed to neutralize MV. This finding was unexpected as OPG 153 has been reported to be associated exclusively with the MV form of VACV (Ulaeto, et al., 1996), necessitating further studies to address the biological role of OPG 153 and its localization on MPXV virions. Nonetheless, the inventor’s work suggests that OPG 153 represents a promising target for preventive and therapeutic monoclonals and vaccines for MPXV and potentially other pathogenic orthopoxviruses.

[0006] Consistent with the inventor's findings, Tai et al. reported a systematic mRNA immunization screen of 34 MPXV surface proteins and found that full-length OPG 153 was able to induce nAbs against MPXV, although neutralization was observed only against MV (Tai, et al., 2025). They further demonstrated that an mRNA vaccine encoding OPG153 and 11 other MPXV antigens conferred protection against MPXV challenge in mice (Tai, et al., 2025). In the inventor's study, immunization with the purified N-terminal domain of OPG 153 as a monovalent subunit vaccine antigen elicited nAb titers significantly higher than those achieved following MVA-BN immunization (FIG. 5).24922-1531-8179, v. 1

[0007] Collectively, this work supports OPG153 as a conserved and compelling target for next-generation orthopoxvirus vaccines. Monoclonal antibodies and single-antigen vaccines that protect across clades and morphologies represent promising orthopoxvirus therapeutics and may reduce manufacturing costs, thereby allowing for equitable access to low-and middle -income countries. Finally, the antibody- and antigen-discovery approach described here shows how Al-driven approaches can significantly accelerate the identification and development of unexploited targets for vaccines and therapeutics. Similar approaches can be used for emerging viral pathogens, antimicrobial-resistant bacteria, fungi, and parasites, leading to highly effective and affordable countermeasures for worldwide deployment.SUMMARY

[0008] Provided herein are engineered proteins comprising an engineered monkeypox virus (MPXV) OPG153 protein globular domain comprising or consisting of a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to amino acids 1-359 of SEQ ID NO: 1 or 2. The MPXV OPG153 globular domain may comprise amino acids 1-360, 1-361, 1-362, 1-364, 1-366, 1-367, 1-368, or 1-369 of SEQ ID NO: 1 or 2, preferably amino acids 1-366 of SEQ ID NO: 1 or 2. The engineered protein may lack the C-terminal helical domain of MPXV OPG153.

[0009] The MPXV OPG153 globular domain may comprise at least one substitution at a position selected from the group consisting of: S196; S322; T353: N194; N320; N351; V20; A21; A25; 144: S45; N50; 156: A62; D67; L81; 186; L96; A97; D100; 1112; 1115; VI 18; 1125; C128; H135; C162; 1165; L174; 1176; V193; G195; L217; A220; 1227; G229; F231; L232; L237; L243; S250; L251; G262; S264P; V265; 1269; D275; A276; 1277; A292; D305; N309; R312; 1319; V325; 1328; H329; T335Q; I338W; 1345; S347; S348; A349; N351; A352; 1125; 1183; 1129; 1165; A161; L189; S185: S228; S250; L237; S273: G331; S252; K47; D310; N309; N50; L81; and 1141, wherein the positions are relative to SEQ ID NO: 1 or 2.

[0010] The MPXV OPG153 globular domain may comprise at least one substitution or substitution set selected from the group consisting of: S 196A; S322A; T353 A; N 194Q; N320Q; N351Q; V20N; V20P; A21P; A25D; A25N; I44F; I44N; I44Q; S45P; N50D; N50E; N50Q; I56W; A62P; D67P; L81P; I86P; L96P; A97P; D100N; I112P; I115P; V118P; I125E; C128S; H135W; C162S; C128S / C162S; I165E; L174P; I176P; V193P; G195I; G195M; L217E;34922-1531-8179, v. 1A220Q; A220T; I227P; G229P; F231Y; L232P; L237P; L237W; L237Q; L243P; S250Q; L251Q; G262F; G262I; G262T; S264E; S264P: V265P; I269Q; I269W; D275L; D275M; A276I; A276V; I277W; A292V; D305P; N309V; R312H; R312I; I319Y; V325T; I328T; H329Y; T335W; T335Y; T335N; T335M; T335Q; I338E; I338F; I338Q; I338W; I345F; S347Q; S347N; S348N; S348T; S348Q; A349P; N351E; N351Q; A352P; I125C / I183C; I129C / I165C; A161C / L189C; S185C; S185C / C162C; S228C / S250C; L237C / S273C; G331C / S252C; K47C / D310C: K47C / N309C; N50C / N309C; N50C / R312C; and L81C / I141C, wherein the positions are relative to SEQ ID NO: 1 or 2.

[0011] The engineered MPXV OPG153 globular domain may be fused or conjugated to a heterologous polypeptide. For example, the engineered MPXV OPG153 globular domain may be fused or conjugated to a membrane anchor, transmembrane domain, self-assembling nanoparticle polypeptide, and / or signal sequence. The membrane anchor, transmembrane domain, and / or self-assembling nanoparticle polypeptide may be fused to the C-terminus of the MPXV OPG153 globular domain via a linker. The signal sequence may be fused to the N-terminus of the MPXV OPG153 globular domain.

[0012] The engineered proteins may exhibit improved solubility or stability, as compared to a native MPXV OPG153 protein. The engineered proteins may be immunogenic and / or antigenic.

[0013] Provided herein are nucleic acid molecules comprising a nucleotide sequence that encodes the amino acid sequence of an engineered protein disclosed herein. The nucleic acid molecules may further comprise a DNA expression vector. The nucleic acid molecules may be mRNAs. The nucleic acid molecules may be self-replicating RNA molecules. The nucleic acid molecules may comprise at least one chemical modification. The at least one chemical modification may be selected from the group consisting of pseudouridine, Nl-methylpseudouridine, N1 -ethylpseudouridine, N 1 -ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 2-thio-l-methyl-l-deaza-pseudouri dine, 2-thio-l -methylpseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-l-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2'-0-methyl uridine.44922-1531-8179, v. 1

[0014] Provided herein are pharmaceutical compositions comprising (i) an engineered protein disclosed herein or (ii) a nucleic acid molecule disclosed herein; and a pharmaceutically acceptable carrier. The pharmaceutical composition may further comprise an adjuvant. The pharmaceutical composition may further comprise a further orthopoxvirus (e.g., MPXV) antigen or a nucleic acid encoding a further orthopoxvirus (e.g., MPXV) antigen, such as, for example, one or more of (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 of) A29L, A21L, A30L, A17L, A27L, I2L, H2R, A35R, B6R, MIR, E8L, H3L, A45L, B9R, B16R, C10L, C21L, E7R, F3L, F4L, G6R, H5R, I3L, O2L, Q1L, B12R, and / or C17L or fragments thereof. The pharmaceutical composition may be formulated within a cationic lipid nanoparticle. The pharmaceutical composition may be for use in the treatment or prevention of an orthopoxvirus (such as, e.g., MPXV, VACV, CPXV, and VARV) infection or a disease associated with orthopoxvirus (such as, e.g., MPXV, VACV, CPXV, and VARV) infection in a subject or for use in eliciting an immune response against orthopoxvirus (e.g., MPXV, VACV, CPXV, and VARV). The subject may be a mammal, such as a human. The MPXV may be Clade I or Clade II MPXV.

[0015] Provided herein are methods of preventing orthopoxvirus (e.g., MPXV) infection or a disease associated with orthopoxvirus (e.g., MPXV) infection in a subject or eliciting an immune response in a subject or reducing orthopoxvirus (e.g., MPXV) viral shedding in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition provided herein. The subject may be a mammal, such as a human. The MPXV may be Clade I or Clade II MPXV.

[0016] Provided herein are uses of (i) an engineered protein disclosed herein, (ii) a nucleic acid molecule disclosed herein; or (iii) a pharmaceutical composition provided herein, in the manufacture of a medicament for the treatment or prevention of an orthopoxvirus (e.g., MPXV) infection or a disease associated with orthopoxvirus (e.g., MPXV) infection. The MPXV may be Clade I or Clade II MPXV.

[0017] Provided herein are compositions comprising an engineered protein provided herein bound to an antibody. The antibody may be a neutralizing human monoclonal antibody against orthopoxvirus (e.g., MPXV).

[0018] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the54922-1531-8179, v. 1detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.BRIEF DESCRIPTION OF DRAWINGS

[0019] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0020] FIG. 1. Identification of OPG153 as an antigenic target of MPXV -neutralizing antibodies. (Top) Predicted structural models of MPXV OPG153 (A28L) a-helical domain (coral) and P-sheet domain (light pink) in complex with nAbs 08E11 (blue, left) and 12112 (yellow, right), colored by predicted local distance difference test (pLDDT) scores. Disordered regions of OPG153 (residues 367-435 and 493-520) are omitted for clarity. Bottom) Schematic representation of full-length OPG153 and the truncated expression construct encoding the N -terminal globular domain. Dotted line indicates a disulfide bond.

[0021] FIGS. 2A-2C. Purification of the N-terminal globular domain of OPG153. (A) Schematic representation of the OPG153 globular domain construct used for recombinant expression. The dotted line indicates a disulfide bond. (B) Recombinant MPXV OPG153 N-temiinal globular domain was purified by Strep-Tactin XT affinity chromatography, followed by Size-exclusion chromatography on a Superdex 200 Increase 10 / 300 column equilibrated in PBS. Fractions corresponding to the dotted line were analyzed in (C). (C) Coomassie blue-stained reducing NuPAGE 4%-12% Bis-Tris gel. Positions of the molecular weight standards are shown on the left, in kDa.

[0022] FIGS. 3A-3B. Binding kinetics of isolated antibodies to orthopoxvirus antigens. (A) (Top) Surface plasmon resonance binding analysis of Fabs from monoclonal antibodies 08E11 (top), 12112 (middle), and 02M12 (bottom) binding to the globular domains of OPG153 from MPXV (left), CPXV (middle), VACV (right). Kinetic parameters were calculated to assess binding affinities. Experimental data (black) were fitted using a 1:1 binding model (red). (Bottom) Biolayer interferometry characterization of AHC biosensor tips capturing IgGs 08E11 and 12112 binding to orthopoxvirus OPG153 (1-366) proteins. VARV proteins were generated64922-1531-8179, v. 1by introducing corresponding epitope mutations into the MPXV OPG153 globular domain background. (B) Biolayer interferometry analysis of mAbs 01G09, 04M05, 13B11, and 13D15 to the ectodomains of known-neutralization targets OPG95, OPG108, OPG120, OPG154, OPG161, and OPG190 at 300 nM antigen concentration. Experimental data were fit to a 1:1 binding model (colored curves). Binding models for positive-control antibodies for OPG95 (7D11), OPG108 (VACV-314), OPG120 (LA5), OPG154 (VACV-302), OPG161 (A20G2), and OPG190 (hMB668) are shown in red.

[0023] FIGS. 4A-4C. OPG153-specific nAbs recognize distinct antigenic sites. (A) Heatmaps showing the flow cytometry-based binding activity (left) and competition against 12112 or 08E11 (right) for the 12 nAbs. Binding was defined as >50% of Alexa488+; competition was determined by >40% reduction in fluorescent signal. Antibodies VACV-22 (anti-OPG161; MPXV A35), VACV-249 (anti-OPG120; MPXV-E8) (Gilchuk et al., 2016), and an unrelated monoclonal antibody (mAb) were used as negative controls. (B) Cryo-EM structural models of MPXV OPG153 bound to Fabs from 08E11 (blue), 12112 (yellow), and 02M12 (green). Insets display close-up views of molecular interactions, including hydrogen bonds and salt bridges (dotted black lines). (C) Surface presentation of OPG153 globular domain showing epitope footprints for 08E11 (group I), 12112 (group III), and 02M12 (group IV) as defined in (B), with colors corresponding to Fab assignments.

[0024] FIGS. 5A-5C. OPG153 globular domain immunization elicits cross¬ neutralizing antibody responses in BALB / c mice. ( A) Schematic overview and timeline of the immunization study performed in BALB / c mice. (B) Neutralization titers elicited by immunization with OPG153, MVA-BN. or SARS-CoV-2 S protein, measured against MPXV- lib virus (comprising both MV and EV viral forms), MPXV-IIb MV, and MPXV -lib EV. (C) Neutralization titers elicited against VACV. Statistical significance among groups was established using Tukey’s multiple comparisons test one-way ANOVA (95% confidence interval). Serum neutralization titers are shown as Logio values. Black lines indicate group medians; dotted lines represent the lower limit of detection (LLD).

[0025] FIG. 6. Coomassie blue-stained reducing NuPAGE 4%-12% Bis-Tris gel of OPG153 stabilizing variants. Positions of the molecular weight standards are shown on the left, in kDa.74922-1531-8179, v. 1

[0026] FIG. 7. Secondary structure, sequence alignment, and evolutionary conservation of neutralization epitopes of orthopoxvirus OPG153. (A) Multiple sequence alignment of residues 1-366 of OPG153 from MPXV, VACV, CPXV, and VARV, with residues involved in antibody interactions indicated by colored circles. The secondary structure of OPG153 is annotated above the sequence alignment. Variable positions across orthopoxvirus sequences are highlighted in yellow. (B) Structural representation of OPG153 sequence conservation in (A). Binding sites for mAbs 08E11 (blue, left), 12112 (yellow-orange, middle), and 02M12 (green, right) are outlined.

[0027] FIG. 8. Differential scanning fluorinietry (DSF) analysis of OPG153 variant thermostability. All variants were prepared at a concentration of 0.3 mg / mL with a final concentration of 3X SYPRO Orange Protein Gel Stain (Sigma-Aldrich) in a white, opaque 96-well plate. 15 fluorescence measurements (Lex = 465 nm, Zem = 580 nm) were taken per °C using a Roche LightCycler 480 II. Data were plotted as the derivative of the melting curve. Each curve is an average of three technical replicates.

[0028] FIG. 9. TGX Stain-Free Gels of OPG153 variant expression. Protein was expressed in 100 mb TB cultures in BL21(DE3) using a pET28b vector. Cells were lysed with BugBuster Master Mix, clarified and purified using StrepXT resin. StrepXT elution was run on Mini-PROTEAN TGX Stain-Free Precast Gels as shown.

[0029] FIG. 10. Biolayer Interferometry of OPG153 combination designs and IgGs. IgG were immobilized on ACH2 tips dipped into 200 nM Antigen HBS P+ (w / BSA).

[0030] FIG. 11. Expression analysis of C-terminal variants and removal of free cystines. Expression in 80 mL Freestyle cells.DETAILED DESCRIPTION

[0031] Provided herein are immunogenic antigens comprising the globular domain of the monkeypox vims (MPXV) antigen OPG153 (MPXVgpl38: A28L), which corresponds to amino acid residues 1-366 of SEQ ID NO: 1 or 2. Immunization with MPXV OPG153 elicited broadly neutralizing antibodies against both MPXV virion forms and VACV. As such, these immunogenic antigens, as either protein molecules or as encoded by a nucleic acid molecule, may be used in immunogenic compositions (i.e., vaccines) to elicit neutralizing antibody responses to protect against monkeypox infection.84922-1531-8179, v. 11. Engineered MPXV OPG153 Protein Globular Domains

[0032] Orthopoxvirus is a genus encompassing a number of viral species including monkeypox virus, vaccinia virus, cowpox virus and variola vims. Some orthopoxviruses are restricted in the hosts they infect, while others have been identified in a broad range of host species. Orthopoxvirues share a number of biological phenotypes including: a lack of a specific receptor required for infection of mammalian cells, a relatively low mutation rate, environmental stability of the virion, and the ability to infect hosts via a number of routes (e.g., mucosal, respiratory, parenteral, etc.).

[0033] Monkeypox virus (MPXV) belongs to the Orthopoxvirus genus in the Poxviridae family. Orthopoxviruses also include, for example, vaccinia vims (VACV, e.g., Vaccinia vims Ankara, Vaccinia vims Copenhagen, Vaccinia vims WR), rabbitpox vims, buffalopox vims, camelpox vims, Cantagalo vims, ectromelia vims (ECTV, mousepox), borealpox vims (AKPV, BRPV”, Alaskpapox), cowpox vims (CPXV), and variola vims (VARV, smallpox).

[0034] Like smallpox vims and vaccinia vims, the MPXV virion contains a linear, double-stranded DNA genome having approximately 250 open reading frames (ORFs) (see, e.g., Lansiaux et al., 2022). The virions exist in two antigenically distinct forms: intracellular mature virions (MVs) and extracellular enveloped virions (EVs). For infection, the vims particle attaches to the host cell through recognition of cell surface glycosaminoglycans and then enters the host cells through various viral-host protein interactions. MPXV reproduce in the cytoplasm using host ribosomes to generate the structural components of virions. Progeny orthopoxviruses are enveloped by membranes before exiting infected cells via plasma membrane fusion or by cell rupture.

[0035] OPG153 is a ~60 kDa polypeptide that localizes to the MPXV viral envelope and is involved in viral entry into host cells and for cell-cell fusion (syncytium formation). MPXV OPG153 sequences include, e.g., UniProt accession number Q8V4V0, V9NSD8, V9NNF4, V9NKU4, V9NWM3, V9NR63, A0A0F7GAP0, A0A2L1F535, A0A0F7G921, A0A0F7GB12, and A0A7H0DNC4, each of which is incorporated herein by reference in its entirety. Exemplary MPXV OPG153 amino acid sequences are provided in SEQ ID NO: 1 and 2. SEQ ID NO: 2 corresponds to accession number YP_010377134.1.94922-1531-8179, v. 1

[0036] There are various approaches for stabilizing the OPG153 protein globular domain. For example, specific locations within the OPG153 protein globular domain may be cross-linked, and mutant forms of the OPG153 protein globular domain that can facilitate the formation of such cross-links may be provided. Pairs of core -facing residues less than 5 A apart may be replaced with aromatic sidechains or pairs of aromatic and positively charged sidechains to favor pi-pi or pi-cation interactions, respectively. Alternatively, residues may be replaced with extended or bulkier hydrophobic sidechains in efforts to fill pre-existing internal cavities. Disulfide bonds may be designed to increase overall stability. The charged or polar substitutions may establish hydrogen bonds or salt bridges with native residues that are predicted to be within 4.0 A. As such, an engineered OPG153 protein globular domain or engineered protein may comprise (i) at least one engineered disulfide bond; (ii) at least one cavity filling substitution; (iii) at least one substitution that provides an electrostatic or polar interaction; (iv) at least one proline substitution and / or (v) a C-terminal extension. The mutations may enhance the expression yield and / or thermostability of the MPXV OPG153 protein.

[0037] The engineered OPG153 protein globular domains or engineered proteins may include at least one mutation selected from any one of the mutations, or sets of mutations, in Table 1. The amino acid sequence of the base construct for the OPG153 globular domain (i.e., without any N-terminal or C-terminal modifications) corresponds to amino acids 1-366 of SEQ ID NO: 1 or 2. The substitutions in each of the constructs described in Table 1 were introduced into the base construct’s OPG153 protein globular domain having an amino acid sequence corresponding to amino acids 1-366 of SEQ ID NO: 1 or 2. The substitutions in each of the constructs described in Table 1 may be introduced into a OPG153 protein globular domain having an amino acid sequence corresponding to amino acids 1-359, 1-360, 1-361, 1-362, 1-364, 1-367, 1-368, or 1-369 of SEQ ID NO: 1 or 2.

[0038] The engineered protein may further include a signal sequence at the N-terminus. The signal sequence may be a human signal sequence or a non-human signal sequence. For example, such a human secretion signal may comprise or consist of the amino acid sequence ofMDWIWRILFLVGAATGAHS (SEQ ID NO:5) (husec2);MRVMAPRTLILLLSGALALTETWAGS (SEQ ID NO:6);MGGAAARLGAVILFVVIVGLHGVRSKY (SEQ ID NO:7) (HSV-1 gD);104922-1531-8179, v. 1MGRLTSGVGTAALLVVAVGLRVVCA (SEQ ID N0:8) (HSV-2 gD);MDWIWRILFLVGAATGAHSQM (SEQ ID N0:9) (human Ig heavy chain);MDWTWRVFCLLAVAPGAHS (SEQ ID NO: 10) (human Ig heavy chain);MKCLLTLAFLFIGVNCA (SEQ ID NO: 11) (VSVg protein);MWLVSLAIVTACAGA (SEQ ID NO: 12) (JEV);MFVFLVLLPLVSSQC (SEQ ID NO; 13).The signal sequence may comprise a sequence having 1, 2, 3, 4, or 5 amino acid differences relative to any of the foregoing exemplary signal sequences.

[0039] When the engineered protein includes a signal sequence at the N-terminus, such as, for example, when it is administered to a subject as an mRNA therapeutic, the engineered OPG153 protein globular domain may include an amino acid modification to reduce the number of N-linked glycosylation sites present sequence (e.g., as compared to a reference). Without wishing to be bound by any particular scientific theory, reduction in the number of N-linked glycosylation sites can be advantageous at least in part because OPG153 expressed during viral infection is not subject to N-linked glycosylation, but the engineered OPG153 globular domain-containing proteins expressed from a polyribonucleotide of the present disclosure (e.g., when delivered to a host for vaccination against MPXV) may acquire N-linked glycans. This may occur, for example, where a polyribonucleotide-encoded antigen of the present disclosure is operably linked with a signal peptide that targets the antigen to the host secretory system. Such acquisition of N-linked glycans by polyribonucleotide-encoded antigens would potentially introduce structures and / or features (e.g., epitopes) that are not present in virally expressed antigens, and / or eliminate structures and / or features (e.g., epitopes) that are present in virally expressed antigens, potentially reducing vaccine efficacy. For example, the engineered OPG153 protein globular domain may include an amino acid modification in which an asparagine (N) residue is substituted, e.g., with a glutamine (Q) residue as compared to a reference sequence in the context of an N-X-T / S N-linked glycosylation motif of the reference sequence. For example, when the engineered protein is to be administered as an mRNA therapeutic, one or more of the glycan removal substitutions in Table 1 are included.

[0040] The engineered protein may further comprise one or more affinity tag at the C-terminus. Exemplary affinity tags include, but are not limited to: AviTag (GLNDIFEAQKIEWHE (SEQ ID NO: 14), which allows biotinylation by BirA, and thereafter,114922-1531-8179, v. 1binding by streptavidin); Calmodulin-tag (KRRWKKNFIAVSAANRFKKISSSGAL (SEQ ID NO:15), which binds calmodulin); S-tag (KETAAAKFERQHMDS (SEQ ID NO:16), which binds to S-protein); SBP-tag (MDEKTTGWRGGHVVEGLAGELEQLRARLEHHPQGQREP (SEQ ID NO: 17), which binds to streptavidin); Strep-tag II (WSHPQFEK (SEQ ID NO: 18), which binds to streptavidin or streptactin); Isopeptag (TDKDMTITFTNKKDAE (SEQ ID NO: 19), which binds covalently to pilin-C protein); Spytag (AHIVMVDAYKPTK (SEQ ID NO:20), which binds to SpyCatcher protein), and polyhistidine tag (e.g., 6xH, which binds to Ni-NTA).

[0041] The engineered protein may further comprise a transmembrane domain. Exemplary transmembrane domains include, but are not limited to:CD3c (murine; LCYLLDGILFIYGVIITALYL (SEQ ID NO:21));CD4 (murine; VFLACVLLGGSFGFLGFLGLCILC (SEQ ID NO:22));CD8a (human; IWAPLAGTCGVLLLSLVITLY (SEQ ID NO:23));CD28 (human; FWVLVVVGGVLACYSLLVTVAFIIFWV (SEQ ID NO:24)): dGCN4 (murine; MKQLEDKIEELLSKIYHLENEIARLKKLIGEGA (SEQ ID NO:25)); GCN4-pl (RMKQLEDKVEELLSKNYHLENEVARLKKLVGER (SEQ ID NO:26));VSV-G (SSIASFFFIIGLIIGLFLVL (SEQ ID NO:27));Influenza HA (WILWISFAISCFLLCVVLLGFIMWACQ (SEQ ID NO:28));PDGFRb (human; VVISAILALVVLTIISLIILIMLWQK (SEQ ID NO:29));SARS-CoV-2 Spike (IPEAPRDGQAYVRKDGEWVLLST (SEQ ID NO:30));HIV-gp41;tGCN4-pLI (RLKQIEDKLEEILSKLYHIENELARIKKLLGER (SEQ ID NO:31)); andInfluenza NA (NISNTNFAAGQSVVSVKLAGNSS (SEQ ID NO:32)).

[0042] The engineered OPG153 protein globular may be fused or conjugated to a trimerization domain. The trimerization domain may comprise a T4 fibritin trimerization domain; a GCN4 domain; a 4J4A domain; a two-helix bundle comprising complementary first heptad repeat (HR1) and second heptad repeat (HR2) regions; or a combination thereof. The trimerization domain may be fused to the C-terminus of the OPG153 protein globular via a linker.124922-1531-8179, v. 1

[0043] The engineered protein may further comprise an amino acid sequence for nanoparticle self-assembly. Non-limiting examples of self-assembling protein nanoparticles include ferritin nanoparticles, 153-50 nanoparticles, I53-DN5 nanoparticles, encapsulin nanoparticles, Sulfur Oxygenase Reductase (SOR) nanoparticles, and lumazine synthase nanoparticles, which are comprised of an assembly of monomeric subunits including ferritin proteins, encapsulin proteins, SOR proteins, and lumazine synthase, respectively. To construct such protein nanoparticles, nucleic acid encoding the engineered protein can be fused to nucleic acid encoding a subunit of the protein nanoparticle (such as a ferritin protein, an encapsulin protein, a SOR protein, a lumazine synthase protein, or a Component A sequence of 153-50 nanoparticles or I53-DN5 nanoparticles (SEQ ID NOs: 3 and 4, respectively)) and expressed in cells under appropriate conditions. The fusion protein self-assembles into a nanoparticle and can be purified.

[0044] For example, an engineered protein can be linked to a ferritin subunit to construct a ferritin nanoparticle. Ferritin nanoparticles and their use for immunization purposes have been disclosed in the art (see, e.g., Kanekiyo et al., Nature, 499:102-106, 2013, incorporated by reference herein in its entirety). Ferritin is a globular protein that is found in all animals, insects, bacteria, and plants, and which acts primarily to control the rate and location of polynuclear Fe(III)2O3 formation through the transportation of hydrated iron ions and protons to and from a mineralized core. The ferritin polypeptide may be insect ferritin, E. coli ferritin, Helicobacter pylori ferritin, human light chain ferritin, bullfrog ferritin or a hybrid thereof, such as E. co / z'-human hybrid ferritin, E. co / -bull frog hybrid ferritin, or humanbullfrog hybrid ferritin. Exemplary amino acid sequences of ferritin polypeptides and nucleic acid sequences encoding ferritin polypeptides for use to make a ferritin nanoparticle can be found in GENBANK®, for example at accession numbers ZP_03085328, ZP_06990637, EJB64322.1, AAA35832, NP_000137 AAA49532, AAA49525, AAA49524 and AAA49523, which are specifically incorporated by reference herein in their entirety as available Apr. 10, 2015.Table 1. MPXV OPG153 protein substitutions134922-1531-8179, v. 114 4922-1531-8179, v. 115 4922-1531-8179, v. 1

[0045] The engineered OPG153 protein globular domains or engineered proteins may have certain amino acids that are not changed relative to the sequence of SEQ ID NO: 1 or 2. For example, the amino acid at any one or more of the following positions may be unchanged relative to the sequence of SEQ ID NO: 1 or 2: 31, 32, 35-42, 87, 92, 96, 104, 105, 107-117, 124, 128, 131, 133-140, 142, 144, 145, 150, 152, 153, 156, 157, 160, 163, 164, 167, 171, 174-177, 192, 194, 196, 197, 200, 201, 203-208, 210, 211, 214, 235, 270-272, 278, 291, 293-305, 310, 317, 319, 321, 323-326, 328, 329, 332, 340-343, 349, 350, 352-355, 357, 363, and 364. Preferably, position(s) 92. 114, 136, 150, 153, 156, 197, 201, 205, 207, 235, 300, 310, 321, 323, 343, and / or 355 are unchanged relative to the sequence of SEQ ID NO: 1 or 2.

[0046] When reference is herein made to specific amino acid residues or specific amino acid regions in the MPXV OPG153 protein by referring to their amino residue number or numbers (such as amino acid residues 75, 80, 215, or 279, for example), and unless otherwise164922-1531-8179, v. 1stated, the numbering is based on the MPXV OPG153 amino acid sequences provided herein in the sequence listing (see, for example, SEQ ID NO: 1 or 2). However, it should be noted, and one of skill in the art will understand, that different MPXV OPG153 sequences may have different numbering systems, for example, if there are additional amino acid residues added or removed as compared to SEQ ID NO: 1 or 2. As such, it is to be understood that when specific amino acid residues are referred to by their number, the description is not limited to only amino acids located at precisely that numbered position when counting from the beginning of a given amino acid sequence, but rather that the equivalent / corresponding amino acid residue in any and all MPXV OPG153 sequences is intended - even if that residue is not at the same precise numbered position, for example if the MPXV OPG153 sequence is shorter or longer than SEQ ID NO: 1 or 2, or has insertions or deletions as compared to SEQ ID NO: 1 or 2. One of skill in the art can readily determine what is the corresponding / equivalent amino acid position to any of the specific numbered residues recited herein, for example by aligning a given MPXV OPG153 sequence to SEQ ID NO: 1 or 2 or to any of the other MPXV OPG153 amino acid sequences provided herein.

[0047] Provided herein are MPXV OPG153 protein and polypeptide amino acid sequences, and compositions and methods comprising such sequences. However, the MPXV OPG153 protein and polypeptide amino acid sequences are not limited to the specific MPXV OPG153 sequences disclosed herein. Variations, modifications and derivatives of the specific sequences provided herein are contemplated.Table 2. Sequence conservation of OPG153 globular domain in strains of MPXV174922-1531-8179, v. 1Substitutions and identities are listed for the consensus sequence of the N-terminal globular domain (1-366) of OPG153.* OPG153 sequence used in this study.Democratic Republic of Congo (DRC)184922-1531-8179, v. 1II. Protein Preparation

[0048] The protein described herein may be prepared by routine methods known in the art, such as by expression in a recombinant host system using a suitable vector. Suitable recombinant host cells include, for example, insect cells, mammalian cells, avian cells, bacteria, and yeast cells. Examples of suitable insect cells include, for example, Sf9 cells, Sf21 cells, Tn5 cells, Schneider S2 cells, and HIGH FIVE cells (a clonal isolate derived from the parental Trichoplusia ni BTI-TN-5B1-4 cell line). Examples of suitable mammalian cells include Chinese hamster ovary (CHO) cells, ExpiCHO-S cells, human embryonic kidney cells (HEK293 or Expi 293 cells, typically transformed by sheared adenovirus type 5 DNA), NIH-3T3 cells, 293-T cells, Vero cells, and HeLa cells. Suitable avian cells include, for example, chicken embryonic stem cells (e.g., EBx.®. cells), chicken embryonic fibroblasts, chicken embryonic germ cells, quail fibroblasts (e.g., ELL-O), and duck cells. Suitable insect cell expression systems, such as baculovirus-vectored systems, are known to those of skill in the art. Materials and methods for some mammalian cell and baculovirus / insect cell expression systems are commercially available in kit form. Avian cell expression systems are also known to those of skill in the art. Similarly, bacterial and mammalian cell expression systems are also known in the art.

[0049] A number of suitable vectors for expression of recombinant proteins in insect or mammalian cells are well-known and conventional in the art. Suitable vectors can contain a number of components, including, but not limited to one or more of the following: an origin of replication; a selectable marker gene; one or more expression control elements, such as a transcriptional control element (e.g., a promoter, an enhancer, a terminator), and / or one or more translation signals; and a signal sequence or leader sequence for targeting to the secretory pathway in a selected host cell (e.g., of mammalian origin or from a heterologous mammalian or non-mammalian species). For example, for expression in insect cells a suitable baculovirus expression vector, such as PFASTBAC, is used to produce recombinant baculovirus particles. The baculovirus particles are amplified and used to infect insect cells to express recombinant protein. For expression in mammalian cells, a vector that will drive expression of the construct in the desired mammalian host cell (e.g., Chinese hamster ovary cells) is used.

[0050] The proteins can be purified using any suitable methods. For example, methods for purifying a protein by immunoaffinity chromatography are known in the art. Suitable methods for purifying desired proteins including precipitation and various types of194922-1531-8179, v. 1chromatography, such as hydrophobic interaction, ion exchange, affinity, chelating and size exclusion are known in the art. Suitable purification schemes can be created using two or more of these or other suitable methods. If desired, the protein may include a “tag” that facilitates purification, such as an epitope tag or a histidine tag. Such tagged proteins can be purified, for example from conditioned media, by chelating chromatography or affinity chromatography. III. Nucleic Acids Encoding Proteins

[0051] Also provided are nucleic acid molecules that encode a protein described herein. These nucleic acid molecules include DNA, cDNA, and RNA sequences. Nucleic acid molecules that encode only the ectodomain of the protein are also contemplated. The nucleic acid molecule can be incorporated into a vector, such as an expression vector.

[0052] The nucleic acid may be a self-replicating RNA molecule. The nucleic acid may include a modified RNA molecule. Also provided are compositions comprising a nucleic acid described herein.IV. Formulations and Methods of Use Thereof

[0053] Provided herein are compositions and methods of using the proteins described herein, or a nucleic acid encoding the proteins described herein. For example, the proteins described herein can be delivered directly as a component of an immunogenic composition or a vaccine. Alternatively, nucleic acids that encode the proteins described herein can be administered to produce the protein or immunogenic fragment in vivo. Protein formulations, recombinant nucleic acids (e.g., DNA, RNA, mRNA, self-replicating RNA, or any variation thereof) and / or viral vectors (e.g., live, single-round, non-replicative assembled virions, or otherwise virus-like particles, or alphavirus replicon particles (VRPs)) that contain sequences encoding the proteins provided herein may be included in a composition.

[0054] Also provided are compositions including a polynucleotide that may elicit an immune response in a mammal. The polynucleotide encodes at least one polypeptide of interest, e.g., an antigen. Antigens disclosed herein may be wild type (i.e., derived from the infectious agent) or preferably modified (e.g., engineered, designed or artificial). The nucleic acid molecules described herein, specifically polynucleotides, may encode one or more engineered OPG153 globular domain-containing protein. Such peptides or polypeptides may serve as an antigen or antigenic molecule. The term “nucleic acid” includes any compound that204922-1531-8179, v. 1includes a polymer of nucleotides. These polymers are referred to as “polynucleotides.” Exemplary nucleic acids or polynucleotides include, but are not limited to, ribonucleic acids (RNAs), including mRNA, and deoxyribonucleic acids (DNAs).

[0055] The composition may include DNA encoding an engineered OPG153 globular domain-containing protein or fragment thereof described herein. The composition may include RNA encoding an engineered OPG153 globular domain-containing protein or fragment thereof described herein. The composition may include an mRNA polynucleotide encoding an engineered OPG153 globular domain-containing protein or fragment thereof described herein. Such compositions may produce the appropriate protein conformation upon translation.

[0056] The composition may include at least one polynucleotide encoding two or more antigenic polypeptides or an immunogenic fragment or epitope thereof. The composition may include two or more polynucleotides encoding two or more antigenic polypeptides or immunogenic fragments or epitopes thereof. The one or more antigenic polypeptides may be encoded on a single polynucleotide or may be encoded individually on multiple (e.g., two or more) polynucleotides.

[0057] A composition may include (a) a polynucleotide encoding an engineered OPG153 globular domain-containing protein; and (b) a polynucleotide encoding an additional polypeptide.

[0058] An RNA polynucleotide includes any nucleic acid sequence selected from any one of the nucleic acid sequences disclosed herein, or homologs thereof having at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) identity with a nucleic acid sequence disclosed herein. An open reading frame may be codon optimized. A composition may include at least one RNA polynucleotide encoding at least one MPXV OPG153 antigenic polypeptide or an immunogenic fragment thereof and at least one 5' terminal cap. A 5’ terminal cap may be 7mG(5')ppp(5')NImpNp.

[0059] The at least one polynucleotide may have at least one chemical modification. The at least one polynucleotide may further include a second chemical modification. The polynucleotide may be RNA. The at least one polynucleotide having at least one chemical modification may have a 5' terminal cap. The at least one chemical modification may be selected from pseudouridine, N1 -methylpseudouridine, N1 -ethylpseudouridine, Nl-ethylpseudouridine, 2-thiouridine, 4' -thiouridine, 5-methylcytosine, 2-thio-l- 1 -methyl- 1-214922-1531-8179, v. 1deaza-pseudouridine, 2-thio-l-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy -pseudouridine, 4-thio-l-methyl -pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine, and 2'-0-methyl uridine. At least 80% (e.g., 85%, 90%, 95%, 98%, 99%, 100%) of the uracils in the open reading frame may have a chemical modification, optionally wherein the composition is formulated in a lipid nanoparticle. All of the uracils in the open reading frame may have a chemical modification. The chemical modification may be in the 5-position of the uracil. The chemical modification may be an Nl-methyl pseudouridine.

[0060] Provided herein are methods of inducing an immune response in a mammal, the methods including administering to the mammal a composition in an amount effective to induce an immune response, wherein the composition includes a polynucleotide encoding an engineered OPG153 globular domain-containing protein. The immune response may include a T cell response or a B cell response. The method may involve a single administration of the composition. The method may further include administering to the subject a booster dose of the composition. The composition may include a polynucleotide disclosed herein formulated in an effective amount to produce an antigen specific immune response in a mammal.

[0061] The immunogenic composition may include an adjuvant. Exemplary adjuvants to enhance effectiveness of the composition include: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc.; (2) oil-in-water emulsion formulations (with or without other specific adjuvants such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59 (PCT Publ. No. WO 90 / 14837), containing 5% Squalene, 0.5% TWEEN 80, and 0.5% Span 85 formulated into submicron particles using a microfluidizer, (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) RIBI™ adjuvant system (RAS), (Ribi Immunochem, Hamilton, Mont.) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL+CWS (DETOX™); (3) saponin adjuvants, such as QS-21, STIMULON™ (Cambridge Bioscience, Worcester, Mass.), which may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes); (4) Complete Freunds Adjuvant224922-1531-8179, v. 1(CFA) and Incomplete Freunds Adjuvant (IFA); (5) cytokines, such as interleukins (IL-1, IL-2, etc.), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; (6) toll-like receptor agonists; and (7) other substances that act as adjuvants to enhance the effectiveness of the composition. The composition may not include an adjuvant. The composition may further include a lipid nanoparticle. The composition may be formulated in a nanoparticle. The composition may further include a cationic or polycationic compound, including protamine or other cationic peptides or proteins, such as poly-L-lysine (PLL).

[0062] Each of the immunogenic compositions discussed herein may be used alone or in combination with one or more other antigens, the latter either from the same viral pathogen or from another pathogenic source or sources. These compositions may be used for prophylactic (to prevent infection) or therapeutic (to treat disease after infection) purposes.

[0063] The composition may include a “pharmaceutically acceptable carrier," which includes any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as adjuvants. Furthermore, the antigen may be conjugated to a protein carrier, such as a ferritin, or a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, H. pylori, and etc. pathogens. For example, a disclosed engineered OPG153 protein globular domain can be linked to a ferritin subunit to construct a ferritin nanoparticle. Ferritin nanoparticles and their use for immunization purposes have been disclosed in the art (see, e.g., Kanekiyo et al., Nature, 499:102-106, 2013, incorporated by reference herein in its entirety). Ferritin is a globular protein that is found in all animals, insects, bacteria, and plants, and which acts primarily to control the rate and location of polynuclear Fe(III)2O3 formation through the transportation of hydrated iron ions and protons to and from a mineralized core.

[0064] The composition may include a diluent, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.234922-1531-8179, v. 1

[0065] The compositions described herein may include an immunologically effective amount of the polypeptide or polynucleotide, as well as any other of the above-mentioned components, as needed. By “immunologically effective amount,” it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for eliciting an immune response. The immune response elicited may be sufficient, for example, for treatment and / or prevention and / or reduction in incidence of illness, infection or disease. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (e.g., nonhuman primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.

[0066] The composition may be administered parenterally, e.g., by injection, either subcutaneously, intramuscularly, or intradermally. The composition may be administered to the mammal by subcutaneous, intramuscular, or intradermal injection. Additional formulations suitable for other modes of administration include oral and pulmonary formulations, nasal formulations, suppositories, and transdermal applications. Oral formulations may be preferred for certain viral proteins. Dosage treatment may be a single dose schedule or a multiple dose schedule. The immunogenic composition may be administered in conjunction with other immunoregulatory agents.

[0067] Also provided are methods of eliciting an immune response against MPXV, comprising administering to a subject in need thereof an immunologically effective amount of the engineered OPG153 globular domain-containing protein and / or an immunogenic composition described herein, which comprises the proteins, DNA molecules, RNA molecules (e.g., self-replicating RNA molecules or mRNA molecules), or VRPs as described above. The immune response may comprise the production of neutralizing antibodies against MPXV.

[0068] An immune response can comprise a humoral immune response, a cell-mediated immune response, or both. An immune response may be induced against each delivered MPXV protein. A cell-mediated immune response can comprise a Helper T-cell (Th) response, a CD8+ cytotoxic T-cell (CTL) response, or both. The immune response may comprise a humoral immune response comprising antibody-producing B cells, and the antibodies may be neutralizing antibodies.244922-1531-8179, v. 1

[0069] The polypeptide and / or immunogenic composition described herein may also elicit an effective immune response to reduce the likelihood of an MPXV infection of a noninfected mammal, or to reduce symptoms following an infection or in an already infected mammal, e.g., reduce the number of outbreaks, MPXV shedding, and risk of spreading the vims to other mammals.

[0070] Provided herein are methods for reducing MPXV viral shedding in a mammal. Also provided are methods for reducing MPXV viral titers in a mammal. The methods may reduce MPXV nucleic acids in serum in a mammal. The term “viral shedding” is used herein according to its plain ordinary meaning in medicine and virology and refers to the production and release of vims from an infected cell. The vims may be released from a cell of a mammal. Vims may be released into the environment from an infected mammal. Vims may be released from a cell within a mammal.

[0071] The methods may include administering the engineered OPG153 globular domain-containing protein and / or immunogenic composition described herein to a mammal that is infected with or is at risk of an MPXV infection. The reduction in MPXV viral shedding in a mammal is as compared to the viral shedding in mammals that were not administered the engineered OPG153 globular domain-containing protein for prophylactic or therapeutic administration or those same mammals investigated prior to and post administration of the engineered OPG153 globular domain-containing protein for therapeutic administration.

[0072] The engineered OPG153 globular domain-containing proteins and / or immunogenic compositions described herein may induce neutralizing antibody production in a subject to which the proteins and / or immunogenic compositions are administered.

[0073] The engineered OPG153 globular domain-containing proteins and / or immunogenic compositions described herein may cross-protect against other orthopoxviruses, such as, e.g., variola, borealpox, ectromelia, cowpox, volepox, buffalopox, camelpox, rabbitpox, or vaccinia viruses. In other words, the engineered OPG153 globular domaincontaining proteins and / or immunogenic compositions described herein may be effective for vaccination against monkeypox and one or more other orthopox viruses. For example, the engineered OPG153 globular domain-containing proteins and / or immunogenic compositions described herein may be effective for vaccination against mpox and smallpox. As another example, the engineered OPG153 globular domain-containing proteins and / or immunogenic254922-1531-8179, v. 1compositions described herein may be effective for vaccination against mpox and a novel orthopox virus.

[0074] The mammal may be a human. The human may be a child, such as an infant. The human may be female, including an adolescent female, a female of childbearing age, a female who is planning pregnancy, a pregnant female, and females who recently gave birth. The human may be a transplant patient or a patient awaiting a transplant.

[0075] A useful measure of antibody potency in the art is “50% neutralization titer.” Another useful measure of antibody potency is any one of the following: a “60% neutralization titer”; a “70% neutralization titer”; a “80% neutralization titer”; and a “90% neutralization titer.” To determine, for example, a 50% neutralizing titer, serum from immunized animals is diluted to assess how dilute serum can be yet retain the ability to block entry of 50% of infectious viruses into cells. For example, a titer of 700 means that serum retained the ability to neutralize 50% of infectious virus after being diluted 700-fold. Thus, higher titers indicate more potent neutralizing antibody responses. The titer may be in a range having a lower limit of about 200, about 400, about 600, about 800, about 1000, about 1500, about 2000, about 2500, about 3000, about 3500, about 4000, about 4500, about 5000, about 5500, about 6000, about 6500, or about 7000. The 50%, 60%, 70%, 80%, or 90% neutralization titer range can have an upper limit of about 400, about 600, about 800, about 1000, about 1500, about 2000, about 2500, about 3000, about 3500, about 4000, about 4500, about 5000, about 5500, about 6000, about 6500, about 7000, about 8000, about 9000, about 10000, about 1 1000, about 12000, about 13000, about 14000, about 15000, about 16000, about 17000, about 18000, about 19000, about 20000, about 21000, about 22000, about 23000, about 24000, about 25000, about 26000, about 27000, about 28000, about 29000, or about 30000. For example, the 50% neutralization titer can be about 3000 to about 6500. “About” means plus or minus 10% of the recited value. Neutralization titer can be measured as described in the specific examples, below.

[0076] An immune response can be stimulated by administering proteins, DNA molecules, RNA molecules (e.g., mRNA molecules, self-replicating RNA molecules or nucleoside modified RNA molecules), or VRPs to an individual, typically a mammal, including a human. The immune response induced may be a protective immune response, i.e., the response reduces the risk or severity of or clinical consequences of an MPXV infection. Stimulating a protective immune response is particularly desirable in some populations particularly at risk from MPXV infection and disease. For example, at-risk populations include264922-1531-8179, v. 1solid organ transplant (SOT) patients, bone marrow transplant patients, and hematopoietic stem cell transplant (HSCT) patients. DNA molecules, RNA molecules, or VRPs can be administered to a transplant donor pre-transplant, or a transplant recipient pre- and / or posttransplant. Because vertical transmission from mother to child is a common source of infecting infants, administering DNA molecules, RNA molecules, or VRPs to a patient who is pregnant or can become pregnant is particularly useful.

[0077] Any suitable route of administration can be used. For example, a composition can be administered intramuscularly, intraperitoneally, subcutaneously, intradermally, or transdermally. Administration may be intra-mucosal, such as intra-orally, intra-nasally, intra-vaginally, and intra-rectally. Compositions can be administered according to any suitable schedule.

[0078] Also provided herein is a method of inhibiting MPXV entry into a cell, comprising contacting the cell with the immunogenic composition described herein.

[0079] A composition may include an engineered OPG153 globular domain-containing protein described herein. A composition may include a nucleic acid molecule or vector encoding such protein. A composition may include a protein described above and a nucleic acid molecule or vector encoding such protein.

[0080] In the case that a nucleic acid molecule encoding an engineered OPG153 globular domain-containing protein is used in a pharmaceutical composition, the nucleic acid molecule may comprise or consist of deoxyribonucleotides and / or ribonucleotides, or analogs thereof, covalently linked together. A nucleic acid molecule as described herein generally contains phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have at least one different linkage, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages, and peptide nucleic acid backbones and linkages. Mixtures of naturally occurring polynucleotides and analogs can be made; alternatively, mixtures of different polynucleotide analogs, and mixtures of naturally occurring polynucleotides and analogs may be made. A nucleic acid molecule may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a274922-1531-8179, v. 1labeling component. The term also includes both double- and single-stranded molecules. Unless otherwise specified or required, the term polynucleotide encompasses both the doublestranded form and each of two complementary single-stranded forms known or predicted to make up the double-stranded form. A nucleic acid molecule is composed of a specific sequence of four nucleotide bases: adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U) for thymine when the polynucleotide is RNA. Thus, the term “nucleic acid sequence” is the alphabetical representation of a nucleic acid molecule. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues.

[0081] The nucleic acids of the present disclosure may comprise one or more modified nucleosides comprising a modified sugar moiety. Such compounds comprising one or more sugar-modified nucleosides may have desirable properties, such as enhanced nuclease stability or increased binding affinity with a target nucleic acid relative to an oligonucleotide comprising only nucleosides comprising naturally occurring sugar moieties. In some embodiments, modified sugar moieties are substituted sugar moieties. In some embodiments, modified sugar moieties are sugar surrogates. Such sugar surrogates may comprise one or more substitutions corresponding to those of substituted sugar moieties.

[0082] In some embodiments, modified sugar moieties are substituted sugar moieties comprising one or more non-bridging sugar substituent, including but not limited to substituents at the 2' and / or 5' positions. Examples of sugar substituents suitable for the 2'-position, include, but are not limited to: 2'-F, 2'-OCH3 (" OMe" or " O-methyl"), and 2'-O(CH2)2OCH3 (" MOE"). In certain embodiments, sugar substituents at the 2' position is selected from allyl, amino, azido, thio, O-allyl, O-C1-C10 alkyl, O-C1-C10 substituted alkyl; OCF3, O(CH2)2SCH3, O(CH2)2-O-N(Rm)(Rn), and 0-CH2-C(=0)-N(Rm)(Rn), where each Rm and Rn is, independently, H or substituted or unsubstituted C1-C10 alkyl. Examples of sugar substituents at the 5'-position, include, but are not limited to: 5'-methyl (R or S): 5'-vinyl, and 5'-methoxy. In some embodiments, substituted sugars comprise more than one non-bridging sugar substituent, for example, T-F-5'-methyl sugar moieties (see, e.g., PCT284922-1531-8179, v. 1International Application WO 2008 / 101157, for additional 5',2'-bis substituted sugar moieties and nucleosides).

[0083] Nucleosides comprising 2'-substituted sugar moieties are referred to as 2'-substituted nucleosides. In some embodiments, a 2'-substituted nucleoside comprises a 2'-substituent group selected from halo, allyl, amino, azido, SH, CN, OCN, CF3, OCF3, O, S, or N(Rm)-alkyl; O, S, or N(Rm)-alkenyl; O, S or N(Rm)-alkynyl; O-alkylenyl-O-alkyl, alkynyl, alkaryl, aralkyl, O-alkaryl, O-aralkyl, O(CH2)2SCH3, O(CH2)2— O— N(Rm)(Rn) or O— CH2— C(=O)— N(Rm)(Rn), where each Rm and Rn is, independently, H, an amino protecting group or substituted or unsubstituted C1-C10 alkyl. These 2'-substituent groups can be further substituted with one or more substituent groups independently selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (NO2), thiol, thioalkoxy (S-alkyl), halogen, alkyl, aryl, alkenyl and alkynyl.

[0084] In some embodiments, a 2'-substituted nucleoside comprises a 2'-substituent group selected from F, NH2, N3, OCF3, O-CH3, O(CH2)3NH2, CH2— CH=CH2, O-CH2— CH=CH2, OCH2CH2OCH3, O(CH2)2SCH3, O-(CH2)2-O-N(Rm)(Rn), O(CH2)2O(CH2)2N(CH3)2, and N-substituted acetamide (O— CH2— C(=O)— N(Rm)(Rn) where each Rm and Rn is, independently, H, an amino protecting group or substituted or unsubstituted Cl -CIO alkyl.

[0085] In some embodiments, a 2'-substituted nucleoside comprises a sugar moiety comprising a 2'-substituent group selected from F, OCF3, O-CH3, OCH2CH2OCH3, O(CH2)2SCH3, O(CH2)2-O-N(CH3)2, -O(CH2)2O(CH2)2N(CH3)2, and O-CH2- C(=O)-N(H)CH3.

[0086] In some embodiments, a 2'-substituted nucleoside comprises a sugar moiety comprising a 2' -substituent group selected from F, O-CH3, and OCH2CH2OCH3.

[0087] In some embodiments, nucleosides of the present disclosure comprise one or more unmodified nucleobases. In certain embodiments, nucleosides of the present disclosure comprise one or more modified nucleobases.

[0088] In some embodiments, modified nucleobases are selected from: universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases as defined herein. 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines,294922-1531-8179, v. 1including 2-aminopropyladenine, 5-propynyluracil; 5-propynylcytosine; 5 -hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl CH3) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine, 3-deazaguanine and 3 -deazaadenine, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases as defined herein. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine([5,4-b][l,4]benzoxazin-2(3H)-one), phenothiazine cytidine (lH-pyrimido[5,4-b][l,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g., 9-(2-aminoethoxy)-H-pyrimido[5,4-13][l,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido|3',2':4,5|pyrrolo|2,3-d|pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in U. S. Patent 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, Kroschwitz, J. I., Ed., John Wiley & Sons, 1990, 858-859; those disclosed by Englisch et al., 1991; and those disclosed by Sanghvi, Y. S., 1993.

[0089] Representative United States Patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include without limitation, U. S. Patents 3,687,808; 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985; 5,681,941; 5,750,692; 5,763,588; 5,830,653 and 6,005,096, each of which is herein incorporated by reference in its entirety.

[0090] Additional modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of 5' terminal nucleotide. For example, one additional modification of the ligand conjugated oligonucleotides of the present disclosure involves chemically linking to the304922-1531-8179, v. 1oligonucleotide one or more additional non-ligand moieties or conjugates which enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., 1989), cholic acid (Manoharan et al., 1994), a thioether, e.g., hexyl-5-tritylthiol (Manoharan et al., 1992; Manoharan et al., 1993), a thiocholesterol (Oberhauser et al., 1992), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., 1991; Kabanov et al., 1990; Svinarchuk et al., 1993), a phospholipid, e.g., di-hexadecyl-rac -glycerol or triethylammonium l,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., 1995; Shea et al., 1990), a poly amine or a polyethylene glycol chain (Manoharan et al., 1995), or adamantane acetic acid (Manoharan et al., 1995), a palmityl moiety (Mishra et al., 1995), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., 1996). In some aspects, a nucleic acid molecule encoding an engineered OPG153 globular domain-containing protein is a modified RNA, such as, for example, a modified mRNA. Modified (m)RNA contemplates certain chemical modifications that confer increased stability and low immunogenicity to mRNAs, thereby facilitating expression of therapeutically important proteins. For instance, Nl-methyl-pseudouridine (Nlm ) outperforms several other nucleoside modifications and their combinations in terms of translation capacity. In some embodiments, the (m)RNA molecules used herein may have the uracils replaced with psuedouracils such as l-methyl-3'-pseudouridylyl bases. In some embodiments, some of the uracils are replaced, but in other embodiments, all of the uracils have been replaced. The (m)RNA may comprise a 5' cap, a 5' UTR element, an optionally codon optimized open reading frame, a 3' UTR element, and a poly(A) sequence and / or a polyadenylation signal.

[0091] The nucleic acid molecule, whether native or modified, may be delivered as a naked nucleic acid molecule or in a delivery vehicle, such as a lipid nanoparticle. A lipid nanoparticle may comprise one or more nucleic acids present in a weight ratio to the lipid nanoparticles from about 5: 1 to about 1: 100. In some embodiments, the weight ratio of nucleic acid to lipid nanoparticles is from about 5:1, 2.5:1, 1:1, 1:5, 1:10, 1:15, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1:50, 1:60, 1:70, 1:80, 1:90, or 1:100, or any value derivable therein.

[0092] In some embodiments, the lipid nanoparticles used herein may contain one, two, three, four, five, six, seven, eight, nine, or ten lipids. These lipids may include triglycerides, phospholipids, steroids or sterols, PEGylated lipids, or a group with an ionizable group such as an alkyl amine and one or more hydrophobic groups such as C6 or greater alkyl groups.314922-1531-8179, v. 1

[0093] In some aspects of the present disclosure, the lipid nanoparticles are mixed with one or more steroid or a steroid derivative. In some embodiments, the steroid or steroid derivative comprises any steroid or steroid derivative. As used herein, in some embodiments, the term “steroid” is a class of compounds with a four ring 17 carbon cyclic structure which can further comprises one or more substitutions including alkyl groups, alkoxy groups, hydroxy groups, oxo groups, acyl groups, or a double bond between two or more carbon atoms.

[0094] In some aspects of the present disclosure, the lipid nanoparticles are mixed with one or more PEGylated lipids (or PEG lipids). In some embodiments, the present disclosure comprises using any lipid to which a PEG group has been attached. In some embodiments, the PEG lipid is a diglyceride which also comprises a PEG chain attached to the glycerol group. In other embodiments, the PEG lipid is a compound which contains one or more C6-C24 long chain alkyl or alkenyl group or a C6-C24 fatty acid group attached to a linker group with a PEG chain. Some non-limiting examples of a PEG lipid includes a PEG modified phosphatidylethanolamine and phosphatidic acid, a PEG ceramide conjugated, PEG modified dialkylamines and PEG modified l,2-diacyloxypropan-3-amines, PEG modified di acylglycerols and dialkylglycerols. In some embodiments, PEG modified diastearoylphosphatidylethanolamine or PEG modified dimyristoyl-sn-glycerol. In some embodiments, the PEG modification is measured by the molecular weight of PEG component of the lipid. In some embodiments, the PEG modification has a molecular weight from about 100 to about 15,000. In some embodiments, the molecular weight is from about 200 to about 500, from about 400 to about 5,000, from about 500 to about 3,000, or from about 1,200 to about 3,000. The molecular weight of the PEG modification is from about 100, 200, 400, 500, 600, 800, 1,000, 1,250, 1,500, 1,750, 2,000, 2,250. 2,500, 2.750, 3,000, 3,500, 4,000, 4,500, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 12,500, to about 15,000. Some non-limiting examples of lipids that may be used in the present disclosure are taught by U. S. Patent 5,820,873, WO 2010 / 141069, or U. S. Patent 8,450,298, which is incorporated herein by reference.

[0095] In some aspects of the present disclosure, the lipid nanoparticles are mixed with one or more phospholipids. In some embodiments, any lipid which also comprises a phosphate group. In some embodiments, the phospholipid is a structure which contains one or two long chain C6-C24 alkyl or alkenyl groups, a glycerol or a sphingosine, one or two phosphate groups, and, optionally, a small organic molecule. In some embodiments, the small organic324922-1531-8179, v. 1molecule is an amino acid, a sugar, or an amino substituted alkoxy group, such as choline or ethanolamine. In some embodiments, the phospholipid is a phosphatidylcholine. In some embodiments, the phospholipid is distearoylphosphatidylcholine or dioleoylphosphatidylethanolamine. In some embodiments, other zwitterionic lipids are used, where zwitterionic lipid defines lipid and lipid-like molecules with both a positive charge and a negative charge.

[0096] In some aspects of the present disclosure, lipid nanoparticle containing compounds containing lipophilic and cationic components, wherein the cationic component is ionizable, are provided. In some embodiments, the cationic ionizable lipids contain one or more groups which is protonated at physiological pH but may deprotonated and has no charge at a pH above 8, 9, 10, 11, or 12. The ionizable cationic group may contain one or more protonatable amines which are able to form a cationic group at physiological pH. The cationic ionizable lipid compound may also further comprise one or more lipid components such as two or more fatty acids with C6-C24 alkyl or alkenyl carbon groups. These lipid groups may be attached through an ester linkage or may be further added through a Michael addition to a sulfur atom. In some embodiments, these compounds may be a dendrimer, a dendron, a polymer, or a combination thereof.

[0097] In some aspects of the present disclosure, composition containing compounds containing lipophilic and cationic components, wherein the cationic component is ionizable, are provided. In some embodiments, ionizable cationic lipids refer to lipid and lipid-like molecules with nitrogen atoms that can acquire charge (pKa). These lipids may be known in the literature as cationic lipids. These molecules with amino groups typically have between 2 and 6 hydrophobic chains, often alkyl or alkenyl such as C6-C24 alkyl or alkenyl groups, but may have at least 1 or more than 6 tails.

[0098] In some embodiments, the amount of the lipid nanoparticle with the nucleic acid molecule encapsulated in the pharmaceutical composition is from about 0.1% w / w to about 50% w / w, from about 0.25% w / w to about 25% w / w, from about 0.5% w / w to about 20% w / w, from about 1% w / w to about 15% w / w, from about 2% w / w to about 10% w / w, from about 2% w / w to about 5% w / w, or from about 6% w / w to about 10% w / w. In some embodiments, the amount of the lipid nanoparticle with the nucleic acid molecule encapsulated in the pharmaceutical composition is from about 0.1% w / w, 0.25% w / w, 0.5% w / w, 1% w / w, 2.5% w / w, 5% w / w, 7.5% w / w, 10% w / w, 15% w / w, 20% w / w, 25% w / w, 30% w / w, 35% w / w, 40%334922-1531-8179, v. 1w / w, 45% w / w, 50% w / w, 55% w / w, 60% w / w, 65% w / w, 70% w / w, 75% w / w, 80% w / w, 85% w / w, 90% w / w, to about 95% w / w, or any range derivable therein.

[0099] In some aspects, the present disclosure comprises one or more sugars formulated into pharmaceutical compositions. In some embodiments, the sugars used herein are saccharides. These saccharides may be used to act as a lyoprotectant that protects the pharmaceutical composition from destabilization during the drying process. These water-soluble excipients include carbohydrates or saccharides such as disaccharides such as sucrose, trehalose, or lactose, a trisaccharide such as fructose, glucose, galactose comprising raffinose, polysaccharides such as starches or cellulose, or a sugar alcohol such as xylitol, sorbitol, or mannitol. In some embodiments, these excipients are solid at room temperature. Some nonlimiting examples of sugar alcohols include erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotritol, maltotetraitol, or a polyglycitol.

[0100] In some embodiments, the amount of the sugar in the pharmaceutical composition is from about 25% w / w to about 98% w / w, 40% w / w to about 95% w / w, 50% w / w to about 90% w / w, 50% w / w to about 70% w / w, or from about 80% w / w to about 90% w / w. In some embodiments, the amount of the sugar in the pharmaceutical composition is from about 10% w / w, 15% w / w, 20% w / w, 25% w / w, 30% w / w, 35% w / w, 40% w / w, 45% w / w, 50% w / w, 52.5% w / w, 55% w / w, 57.5% w / w, 60% w / w, 62.5% w / w, 65% w / w, 67.5% w / w, 70% w / w, 75% w / w, 80% w / w, 82.5% w / w, 85% w / w, 87.5% w / w, 90% w / w, to about 95% w / w, or any range derivable therein.

[0101] In some embodiments, the pharmaceutically acceptable polymer is a copolymer. The pharmaceutically acceptable polymer may further comprise one, two, three, four, five, or six subunits of discrete different types of polymer subunits. These polymer subunits may include polyoxypropylene, polyoxyethylene, or a similar subunit. In particular, the pharmaceutically acceptable polymer may comprise at least one hydrophobic subunit and at least one hydrophilic subunit. In particular, the copolymer may have hydrophilic subunits on each side of a hydrophobic unit. The copolymer may have a hydrophilic subunit that is polyoxyethylene and a hydrophobic subunit that is polyoxypropylene.

[0102] In some embodiments, expression cassettes are employed to express an engineered OPG153 globular domain-containing protein, either for subsequent purification and344922-1531-8179, v. 1delivery to a cell / subject, or for use directly in a viral-based delivery approach. Provided herein are expression vectors which contain one or more nucleic acids encoding an engineered OPG153 globular domain-containing protein.

[0103] Expression requires that appropriate signals be provided in the vectors and include various regulatory elements such as enhancers / promoters from both viral and mammalian sources that drive expression of the engineered OPG153 globular domaincontaining protein in cells. Throughout this application, the term “expression cassette” is meant to include any type of genetic construct containing a nucleic acid coding for a gene product in which part or all of the nucleic acid encoding sequence is capable of being transcribed and translated, i.e.. is under the control of a promoter. A “promoter” refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene. The phrase “under transcriptional control” means that the promoter is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the gene. An “expression vector” is meant to include expression cassettes comprised in a genetic construct that is capable of replication, and thus including one or more of origins of replication, transcription termination signals, poly-A regions, selectable markers, and multipurpose cloning sites.

[0104] The term promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II. Much of the thinking about how promoters are organized derives from analyses of several viral promoters, including those for the EBV thymidine kinase (tk) and SV40 early transcription units. These studies, augmented by more recent work, have shown that promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator or repressor proteins.

[0105] At least one module in each promoter functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the S V40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation.

[0106] Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site,354922-1531-8179, v. 1although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either co-operatively or independently to activate transcription.

[0107] In certain embodiments, viral promoters such as the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter, the Rous sarcoma virus long terminal repeat, rat insulin promoter and glyceraldehyde-3-phosphate dehydrogenase can be used to obtain high-level expression of the coding sequence of interest. The use of other viral or mammalian cellular or bacterial phage promoters which are well-known in the art to achieve expression of a coding sequence of interest is contemplated as well, provided that the levels of expression are sufficient for a given purpose. By employing a promoter with well-known properties, the level and pattern of expression of the protein of interest following transfection or transformation can be optimized. Further, selection of a promoter that is regulated in response to specific physiologic signals can permit inducible expression of the gene product.

[0108] Enhancers are genetic elements that increase transcription from a promoter located at a distant position on the same molecule of DNA. Enhancers are organized much like promoters. That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins. The basic distinction between enhancers and promoters is operational. An enhancer region as a whole must be able to stimulate transcription at a distance; this need not be true of a promoter region or its component elements. On the other hand, a promoter must have one or more elements that direct initiation of RNA synthesis at a particular site and in a particular orientation, whereas enhancers lack these specificities. Promoters and enhancers are often overlapping and contiguous, often seeming to have a very similar modular organization.

[0109] Below is a list of promoters / enhancers and inducible promoters / enhancers that could be used in combination with the nucleic acid encoding a gene of interest in an expression construct. Additionally, any promoter / enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of the gene. Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial364922-1531-8179, v. 1polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct.

[0110] The promoter and / or enhancer may be, for example, immunoglobulin light chain, immunoglobulin heavy chain, T-cell receptor, HLA DQ a and / or DQ |3, P-interferon, interleukin-2, interleukin-2 receptor, MHC class II 5, MHC class II HLA-Dra, [3-Actin, muscle creatine kinase (MCK), prealbumin (transthyretin), elastase I, metallothionein (MTII), collagenase, albumin, a-fetoprotein, t-globin, [ -globin, c-fos, c-HA-ra.v, insulin, neural cell adhesion molecule (NCAM), ai-antitrypain, H2B (TH2B) histone, mouse and / or type I collagen, glucose-regulated proteins (GRP94 and GRP78), rat growth hormone, human serum amyloid A (SAA), troponin I (TN I), platelet-derived growth factor (PDGF), SV40, polyoma, retroviruses, papilloma virus, hepatitis B virus, human immunodeficiency virus, cytomegalovirus (CMV), and gibbon ape leukemia virus.

[0111] Where a cDNA insert is employed, one will typically desire to include a polyadenylation signal to effect proper polyadenylation of the gene transcript. Any polyadenylation sequence may be employed such as human growth hormone and SV40 polyadenylation signals. Also contemplated as an element of the expression cassette is a terminator. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.

[0112] There are a number of ways in which expression vectors may be introduced into cells. In certain embodiments, the expression construct comprises a virus or engineered construct derived from a viral genome. The ability of certain viruses to enter cells via receptor-mediated endocytosis, to integrate into host cell genome and express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign genes into mammalian cells. These have a relatively low capacity for foreign DNA sequences and have a restricted host spectrum. Furthermore, their oncogenic potential and cytopathic effects in permissive cells raise safety concerns. They can accommodate only up to 8 kB of foreign genetic material but can be readily introduced in a variety of cell lines and laboratory animals.

[0113] One method for in vivo delivery involves the use of an adenovirus expression vector. “Adenovirus expression vector” is meant to include those constructs containing adenovirus sequences sufficient to (a) support packaging of the construct and (b) to express an374922-1531-8179, v. 1engineered OPG153 globular domain-containing protein that has been cloned therein. In this context, expression does not require that the gene product be synthesized.

[0114] The expression vector comprises a genetically engineered form of adenovirus. Knowledge of the genetic organization of adenovirus, a 36 kB, linear, double-stranded DNA virus, allows substitution of large pieces of adenoviral DNA with foreign sequences up to 7 kB. In contrast to retro vims, the adenoviral infection of host cells does not result in chromosomal integration because adenoviral DNA can replicate in an episomal manner without potential genotoxicity. Also, adenoviruses are structurally stable, and no genome rearrangement has been detected after extensive amplification. Adenovirus can infect virtually all epithelial cells regardless of their cell cycle stage. So far, adenoviral infection appears to be linked only to mild disease such as acute respiratory disease in humans.

[0115] Adenovims is particularly suitable for use as a gene transfer vector because of its mid-sized genome, ease of manipulation, high titer, wide target cell range and high infectivity. Both ends of the viral genome contain 100-200 base pair inverted repeats (ITRs), which are cis elements necessary for viral DNA replication and packaging. The early (E) and late (L) regions of the genome contain different transcription units that are divided by the onset of viral DNA replication. The El region (E1A and E1B) encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes. The expression of the E2 region (E2A and E2B) results in the synthesis of the proteins for viral DNA replication. These proteins are involved in DNA replication, late gene expression and host cell shut-off. The products of the late genes, including the majority of the viral capsid proteins, are expressed only after significant processing of a single primary transcript issued by the major late promoter (MLP). The MLP, (located at 16.8 m.u.) is particularly efficient during the late phase of infection, and all the mRNAs issued from this promoter possess a 5’-tripartite leader (TPL) sequence which makes them preferred mRNAs for translation. In one system, recombinant adenovirus is generated from homologous recombination between shuttle vector and provirus vector. Due to the possible recombination between two proviral vectors, wild-type adenovirus may be generated from this process. Therefore, it is critical to isolate a single clone of virus from an individual plaque and examine its genomic structure.

[0116] Generation and propagation of the current adenovirus vectors, which are replication deficient, depend on a unique helper cell line, designated 293, which was transformed from human embryonic kidney cells by Ad5 DNA fragments and constitutively384922-1531-8179, v. 1expresses El proteins. Since the E3 region is dispensable from the adenovirus genome, the current adenovirus vectors, with the help of 293 cells, carry foreign DNA in either the El, the E3 or both regions. In nature, adenovirus can package approximately 105% of the wild-type genome, providing capacity for about 2 extra kb of DNA. Combined with the approximately 5.5 kb of DNA that is replaceable in the El and E3 regions, the maximum capacity of the current adenovirus vector is under 7.5 kb, or about 15% of the total length of the vector. More than 80% of the adenovirus viral genome remains in the vector backbone and is the source of vector-borne cytotoxicity. Also, the replication deficiency of the El-deleted virus is incomplete.

[0117] Helper cell lines may be derived from human cells such as human embryonic kidney cells, muscle cells, hematopoietic cells or other human embryonic mesenchymal or epithelial cells. Alternatively, the helper cells may be derived from the cells of other mammalian species that are permissive for human adenovirus. Such cells include, e.g., Vero cells or other monkey embryonic mesenchymal or epithelial cells. As stated above, the preferred helper cell line is 293.

[0118] The adenoviruses of the disclosure are replication defective, or at least conditionally replication defective. The adenovirus may be of any of the 42 different known serotypes or subgroups A-F. Adenovirus type 5 of subgroup C is one exemplary starting material that may be used to obtain the conditional replication-defective adenovirus vector for use in the present disclosure.

[0119] Other viral vectors may be employed as expression constructs in the present disclosure. Vectors derived from viruses such as vaccinia virus, adeno-associated virus (AAV) and herpesviruses may be employed. They offer several attractive features for various mammalian cells.

[0120] In embodiments, particular embodiments, the vector is an AAV vector. AAV is a small virus that infects humans and some other primate species. AAV is not currently known to cause disease. The virus causes a very mild immune response, lending further support to its apparent lack of pathogenicity. In many cases, AAV vectors integrate into the host cell genome, which can be important for certain applications, but can also have unwanted consequences. Gene therapy vectors using AAV can infect both dividing and quiescent cells and persist in an extrachromosomal state without integrating into the genome of the host cell, although in the394922-1531-8179, v. 1native virus some integration of virally carried genes into the host genome does occur. These features make AAV a very attractive candidate for creating viral vectors for gene therapy, and for the creation of isogenic human disease models. Recent human clinical trials using AAV for gene therapy in the retina have shown promise. AAV belongs to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae. The virus is a small (20 nm) replicationdefective, nonenveloped virus.

[0121] The AAV genome is built of single-stranded deoxyribonucleic acid (ssDNA), either positive- or negative-sensed, which is about 4.7 kilobase long. The genome comprises inverted terminal repeats (ITRs) at both ends of the DNA strand, and two open reading frames (ORFs): rep and cap. The former is composed of four overlapping genes encoding Rep proteins required for the AAV life cycle, and the latter contains overlapping nucleotide sequences of capsid proteins: VP1, VP2 and VP3, which interact together to form a capsid of an icosahedral symmetry.

[0122] With regard to gene therapy, ITRs seem to be the only sequences required in cis next to the therapeutic gene: structural (cap) and packaging (rep) proteins can be delivered in trans. With this assumption many methods were established for efficient production of recombinant AAV (rAAV) vectors containing a reporter or therapeutic gene. However, it was also published that the ITRs are not the only elements required in cis for the effective replication and encapsidation. A few research groups have identified a sequence designated cis-acting Rep-dependent element (CARE) inside the coding sequence of the rep gene. CARE was shown to augment the replication and encapsidation when present in cis.

[0123] In some aspects, the present disclosure provides pharmaceutical compositions that contain one or more salts. The salts may be an inorganic potassium or sodium salt such as potassium chloride, sodium chloride, potassium phosphate dibasic, potassium phosphate monobasic, sodium phosphate dibasic, or sodium phosphate monobasic. The pharmaceutical composition may comprise one or more phosphate salts such to generate a phosphate buffer solution. The phosphate buffer solution may comprise each of the phosphates to buffer a solution to a pH from about 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0, or any range derivable therein.

[0124] In some aspects, the present disclosure comprises one or more excipients formulated into pharmaceutical compositions. An “excipient” refers to pharmaceutically404922-1531-8179, v. 1acceptable carriers that are relatively inert substances used to facilitate administration or delivery of an API into a subject or used to facilitate processing of an API into drug formulations that can be used pharmaceutically for delivery to the site of action in a subject. Furthermore, these compounds may be used as diluents in order to obtain a dosage that can be readily measured or administered to a patient. Non-limiting examples of excipients include polymers, stabilizing agents, surfactants, surface modifiers, solubility enhancers, buffers, encapsulating agents, antioxidants, preservatives, nonionic wetting or clarifying agents, viscosity increasing agents, and absorption-enhancing agents.

[0125] The term “pharmaceutically acceptable" may mean approved by a regulatory agency of the Federal or a state government or listed in the U. S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term “carrier” refers to a diluent, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and can preferably include an adjuvant. Water is a particular carrier when the pharmaceutical composition is administered by injections, such an intramuscular injection. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Other suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.

[0126] The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. Oral formulations can include standard earners such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical agents are described in “Remington's Pharmaceutical Sciences.” Such compositions will contain a prophylactically or therapeutically effective amount of the antibody or fragment thereof, preferably in purified form, together with a suitable amount of earner so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration, which can be oral, intravenous, intraarterial, intrabuccal, intranasal, nebulized, bronchial inhalation, or delivered by mechanical ventilation.414922-1531-8179, v. 1

[0127] Engineered proteins or nucleic acids encoding engineered proteins of the present disclosure, as described herein, can be formulated for parenteral administration, e.g., formulated for injection via the intradermal, intravenous, intramuscular, subcutaneous, intra-tumoral or even intraperitoneal routes. The formulation could alternatively be administered by a topical route directly to the mucosa, for example by nasal drops, inhalation, or by nebulizer. Pharmaceutically acceptable salts include the acid salts and those which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

[0128] Generally, the ingredients of compositions of the disclosure are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a hermetically sealed container such as an ampoule or sachet indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

[0129] The compositions of the disclosure can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

[0130] Dosage can be by a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunization schedule and / or in a booster immunization schedule. In a multiple dose schedule the various doses may be given by the same or different routes. Multiple doses will typically be administered at least 1 week apart (e.g., about 2 weeks, about 3 weeks, about 4 weeks, about 6 weeks, about 8 weeks, about 10 weeks, about 12 weeks, about 16 weeks, etc.).424922-1531-8179, v. 1

[0131] The compositions disclosed herein may be used to treat both children and adults. Thus, a human subject may be less than 1 year old, 1-5 years old, 5-16 years old, 16-55 years old, 55-65 years old, or at least 65 years old.

[0132] Preferred routes of administration include, but are not limited to, intramuscular, intraperitoneal, intradermal, subcutaneous, intravenous, intraarterial, and intraocular injection. Particularly preferred routes of administration include intramuscular, intradermal and subcutaneous injection.V. Antibodies and Diagnostic Uses

[0133] The polypeptides described above may be used to produce antibodies, both polyclonal and monoclonal. If polyclonal antibodies are desired, a selected animal or mammal (e.g., mouse, rabbit, goat, guinea pig, horse, etc.) is immunized with an immunogenic polypeptide bearing an MPXV epitope(s). Serum from the immunized animal is collected and treated according to known procedures. If serum containing polyclonal antibodies to an MPXV epitope contains antibodies to other antigens, the polyclonal antibodies can be purified by immunoaffinity chromatography. Techniques for producing and processing polyclonal antisera are known in the art.

[0134] Monoclonal antibodies directed against MPXV epitopes can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies by hybridomas is known. Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA or viruses known to immortalize B lymphocytes, such as EBV. Alternatively, the general methodology for making monoclonal antibodies by single B cell sorting is known. B cells from an immunized or otherwise convalescent human or animal are sorted utilizing the MPXV epitope of interest as a “bait” and epitopes that are not desirable as a negative selection. Isolated B cells are single cell sequenced and the antibody encoding genes are subcloned into an expression vector. Antibodies are subsequently expressed from the expression vector. Panels of monoclonal antibodies produced against MPXV epitopes can be screened for various properties; i.e., for isotype, epitope affinity, neutralizing potency against the virus, etc.

[0135] Antibodies, both monoclonal and polyclonal, which are directed against MPXV epitopes are particularly useful in diagnosis, and those which are neutralizing are useful in434922-1531-8179, v. 1passive immunotherapy. Monoclonal antibodies, in particular, may be used to raise antiidiotype antibodies.

[0136] Both the polypeptides which react immunologically with serum containing MPXV antibodies, and the antibodies raised against these polypeptides, may be useful in immunoassays to detect the presence of anti-MPXV antibodies, or the presence of the virus, in biological samples, including for example, blood or serum samples. Design of the immunoassays is subject to a great deal of variation, and a variety of these are known in the art. For example, the immunoassay may utilize a polypeptide having the sequence set forth in SEQ ID NO: 1 or 2 with any of the changes in Table 1.

[0137] Alternatively, the immunoassay may use a combination of viral antigens derived from the polypeptides described herein. It may use, for example, a monoclonal antibody directed towards at least one polypeptide described herein, a combination of monoclonal antibodies directed towards the polypeptides described herein, monoclonal antibodies directed towards different viral antigens, polyclonal antibodies directed towards the polypeptides described herein, or polyclonal antibodies directed towards different viral antigens. Protocols may be based, for example, upon competition, or direct reaction, or may be sandwich type assays. Protocols may also, for example, use solid supports, or may be by immunoprecipitation. Most assays involve the use of labeled antibody or polypeptide; the labels may be, for example, fluorescent, chemiluminescent, radioactive, or dye molecules. Assays which amplify the signals from the probe are also known; examples of which are assays which utilize biotin and avidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays.

[0138] Kits suitable for immunodiagnostics and containing the appropriate labeled reagents are constructed by packaging the appropriate materials, including the engineered OPG153 globular domain-containing protein containing MPXV epitopes or antibodies directed against epitopes in suitable containers, along with the remaining reagents and materials required for the conduct of the assay, as well as a suitable set of assay instructions.

[0139] The polynucleotide probes can also be packaged into diagnostic kits. Diagnostic kits include the probe DNA, which may be labeled; alternatively, the probe DNA may be unlabeled and the ingredients for labeling may be included in the kit. The kit may also contain444922-1531-8179, v. 1other suitably packaged reagents and materials needed for the particular hybridization protocol, for example, standards, as well as instructions for conducting the test.VI. Immunodetection Methods

[0140] The present disclosure concerns immunodetection methods for binding, purifying, removing, quantifying and otherwise generally detecting MPXV OPG153 protein. While such methods can be applied in a traditional sense, another use will be in quality control and monitoring of vaccine stocks, where antibodies according to the present disclosure can be used to assess the amount or integrity (z'.e., long term stability) of antigens. Alternatively, the methods may be used to screen various antibodies for appropriate / desired reactivity profiles.

[0141] Some immunodetection methods include enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoradiometric assay, fluoroimmunoassay, chemiluminescent assay, bioluminescent assay, Western blot, flow cytometry, and fluorescence-activated cell sorting (FACS) to mention a few. In particular, a competitive assay for the detection and quantitation of MPXV OPG153 protein also is provided. The steps of various useful immunodetection methods have been described in the scientific literature, such as, e.g., Doolittle and Ben-Zeev (1999), Gulbis and Galand (1993), De Jager et al. (1993), and Nakamura et al. (1987). In general, the immunobinding methods include obtaining a sample suspected of containing MPXV OPG153 protein, and contacting the sample with a first antibody in accordance with the present disclosure, as the case may be, under conditions effective to allow the formation of immunocomplexes.

[0142] These methods include methods for detecting or purifying MPXV OPG153 protein from a sample. The antibody will preferably be linked to a solid support, such as in the form of a column matrix, and the sample suspected of containing the MPXV OPG153 protein will be applied to the immobilized antibody. The unwanted components will be washed from the column, leaving the MPXV OPG153 protein-expressing cells immunocomplexed to the immobilized antibody, which is then collected by removing the organism or antigen from the column.

[0143] The immunobinding methods also include methods for detecting and quantifying the amount of MPXV OPG153 protein or related components in a sample and the detection and quantification of any immune complexes formed during the binding process. Here, one would obtain a sample suspected of containing MPXV OPG153 protein and contact454922-1531-8179, v. 1the sample with an antibody that binds MPXV OPG153 protein or components thereof, followed by detecting and quantifying the amount of immune complexes formed under the specific conditions. In terms of antigen detection, the biological sample analyzed may be any sample that is suspected of containing MPXV OPG153 protein, such as a tissue section or specimen, a homogenized tissue extract, a biological fluid (e.g., a nasal swab), including blood and serum, or a secretion, such as feces or urine.

[0144] Contacting the chosen biological sample with the antibody under effective conditions and for a period of time sufficient to allow the formation of immune complexes (primary immune complexes) is generally a matter of simply adding the antibody composition to the sample and incubating the mixture for a period of time long enough for the antibodies to form immune complexes with, i.e., to bind to MPXV OPG153 protein. After this time, the sample-antibody composition, such as a tissue section, ELISA plate, dot blot or Western blot, will generally be washed to remove any non-specifically bound antibody species, allowing only those antibodies specifically bound within the primary immune complexes to be detected.

[0145] In general, the detection of immunocomplex formation is well known in the art and may be achieved through the application of numerous approaches. These methods are generally based upon the detection of a label or marker, such as any of those radioactive, fluorescent, biological and enzymatic tags. Patents concerning the use of such labels include U. S. Patents 3,817,837, 3,850,752, 3,939,350, 3,996,345, 4,277,437, 4,275,149 and 4,366,241. Of course, one may find additional advantages through the use of a secondary binding ligand such as a second antibody and / or a biotin / avidin ligand binding arrangement, as is known in the art.

[0146] The antibody employed in the detection may itself be linked to a detectable label, wherein one would then simply detect this label, thereby allowing the amount of the primary immune complexes in the composition to be determined. Alternatively, the first antibody that becomes bound within the primary immune complexes may be detected by means of a second binding ligand that has binding affinity for the antibody. In these cases, the second binding ligand may be linked to a detectable label. The second binding ligand is itself often an antibody, which may thus be termed a “secondary” antibody. The primary immune complexes are contacted with the labeled, secondary binding ligand, or antibody, under effective conditions and for a period of time sufficient to allow the formation of secondary immune complexes. The secondary immune complexes are then generally washed to remove any non-464922-1531-8179, v. 1specifically bound labeled secondary antibodies or ligands, and the remaining label in the secondary immune complexes is then detected.

[0147] Further methods include the detection of primary immune complexes by a two-step approach. A second binding ligand, such as an antibody that has binding affinity for the antibody, is used to form secondary immune complexes, as described above. After washing, the secondary immune complexes are contacted with a third binding ligand or antibody that has binding affinity for the second antibody, again under effective conditions and for a period of time sufficient to allow the formation of immune complexes (tertiary immune complexes). The third ligand or antibody is linked to a detectable label, allowing detection of the tertiary immune complexes thus formed. This system may provide for signal amplification if this is desired.

[0148] One method of immunodetection uses two different antibodies. A first biotinylated antibody is used to detect the target antigen, and a second antibody is then used to detect the biotin attached to the complexed biotin. In that method, the sample to be tested is first incubated in a solution containing the first step antibody. If the target antigen is present, some of the antibody binds to the antigen to form a biotinylated antibody / antigen complex. The antibody / antigen complex is then amplified by incubation in successive solutions of streptavidin (or avidin), biotinylated DNA, and / or complementary biotinylated DNA, with each step adding additional biotin sites to the antibody / antigen complex. The amplification steps are repeated until a suitable level of amplification is achieved, at which point the sample is incubated in a solution containing the second step antibody against biotin. This second step antibody is labeled, as for example with an enzyme that can be used to detect the presence of the antibody / antigen complex by histoenzymology using a chromogen substrate. With suitable amplification, a conjugate can be produced which is macroscopically visible.

[0149] Another known method of immunodetection takes advantage of the immuno-PCR (Polymerase Chain Reaction) methodology. The PCR method is similar to the Cantor method up to the incubation with biotinylated DNA, however, instead of using multiple rounds of streptavidin and biotinylated DNA incubation, the DNA / biotin / streptavidin / antibody complex is washed out with a low pH or high salt buffer that releases the antibody. The resulting wash solution is then used to carry out a PCR reaction with suitable primers with appropriate controls. At least in theory, the enormous amplification capability and specificity of PCR can be utilized to detect a single antigen molecule.474922-1531-8179, v. 1A. ELISAs

[0150] Immunoassays, in their most simple and direct sense, are binding assays. Certain preferred immunoassays are the various types of enzyme linked immunosorbent assays (ELISAs) and radioimmunoassays (RIA) known in the art. Immunohistochemical detection using tissue sections is also particularly useful. However, it will be readily appreciated that detection is not limited to such techniques, and western blotting, dot blotting, FACS analyses, and the like may also be used.

[0151] In one exemplary ELISA, the antibodies of the disclosure are immobilized onto a selected surface exhibiting protein affinity, such as a well in a polystyrene microtiter plate. Then, a test composition suspected of containing the MPXV OPG153 protein is added to the wells. After binding and washing to remove non-specific ally bound immune complexes, the bound antigen may be detected. Detection may be achieved by the addition of another anti-MPXV OPG153 protein antibody that is linked to a detectable label. This type of ELISA is a simple “sandwich ELISA.’’ Detection may also be achieved by the addition of a second anti-MPXV OPG 153 protein antibody, followed by the addition of a third antibody that has binding affinity for the second antibody, with the third antibody being linked to a detectable label.

[0152] In another exemplary ELISA, the samples suspected of containing the MPXV OPG 153 protein (e.g., potentially infected cells) are immobilized onto the well surface and then contacted with the anti -MPXV OPG 153 protein antibodies of the disclosure. After binding and washing to remove non-specifically bound immune complexes, the bound anti-MPXV OPG153 protein antibodies are detected. Where the initial anti-MPXV OPG153 protein antibodies are linked to a detectable label, the immune complexes may be detected directly. This type of ELISA is a simple “direct ELISA.’’ Again, the immune complexes may be detected using a second antibody that has binding affinity for the first anti-MPXV OPG153 protein antibody, with the second antibody being linked to a detectable label.

[0153] Irrespective of the format employed, ELISAs have certain features in common, such as coating, incubating and binding, washing to remove non-specifically bound species, and detecting the bound immune complexes. These are described below.

[0154] In coating a plate with either antigen or antibody, one will generally incubate the wells of the plate with a solution of the antigen or antibody, either overnight or for a specified period of hours. The wells of the plate will then be washed to remove incompletely484922-1531-8179, v. 1adsorbed material. Any remaining available surfaces of the wells are then “coated” with a nonspecific protein that is antigenically neutral with regard to the test antisera. These include bovine serum albumin (BSA), casein or solutions of milk powder. The coating allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific binding of antisera onto the surface.

[0155] In ELISAs, it is probably more customary to use a secondary or tertiary detection means rather than a direct procedure. Thus, after binding of a protein or antibody to the well, coating with a non-reactive material to reduce background, and washing to remove unbound material, the immobilizing surface is contacted with the biological sample to be tested under conditions effective to allow immune complex (antigen / antibody) formation. Detection of the immune complex then requires a labeled secondary binding ligand or antibody, and a secondary binding ligand or antibody in conjunction with a labeled tertiary antibody or a third binding ligand.

[0156] “Under conditions effective to allow immune complex (antigen / antibody) formation” means that the conditions preferably include diluting the antigens and / or antibodies with solutions such as BSA, bovine gamma globulin (BGG) or phosphate buffered saline (PBS)ZTween, wherein the Tween is frequently Tween 20. These added agents also tend to assist in the reduction of nonspecific background.

[0157] The “suitable” conditions also mean that the incubation is at a temperature or for a period of time sufficient to allow effective binding. Incubation steps are typically from about 1 to 2 to 4 hours or so, at temperatures preferably on the order of 25 °C to 27°C, or may be overnight at about 4°C or so.

[0158] Following all incubation steps in an ELISA, the contacted surface is washed so as to remove non-complexed material. A preferred washing procedure includes washing with a solution such as PBS / Tween, or borate buffer. Following the formation of specific immune complexes between the test sample and the originally bound material, and subsequent washing, the occurrence of even minute amounts of immune complexes may be determined.

[0159] To provide a detecting means, the second or third antibody will have an associated label to allow detection. Preferably, this will be an enzyme that will generate color development upon incubating with an appropriate chromogenic substrate. Thus, for example, one will desire to contact or incubate the first and second immune complex with a urease,494922-1531-8179, v. 1glucose oxidase, alkaline phosphatase or hydrogen peroxidase-conjugated antibody for a period of time and under conditions that favor the development of further immune complex formation (e.g., incubation for 2 hours at room temperature in a PBS -containing solution such as PBS-Tween).

[0160] After incubation with the labeled antibody, and subsequent to washing to remove unbound material, the amount of label is quantified, e.g., by incubation with a chromogenic substrate such as urea, or bromocresol purple, or 2,2'-azino-di-(3-ethyl-benzthiazoline-6-sulfonic acid (ABTS), 3,3',5,5'-tetramethylbenzidine (TMB), or H2O2, in the case of peroxidase as the enzyme label. Quantification is then achieved by measuring the degree of color generated, e.g., using a visible spectra spectrophotometer.B. Western Blot

[0161] The Western blot (alternatively, protein immunoblot) is an analytical technique used to detect specific proteins in a given sample of tissue homogenate or extract. It uses gel electrophoresis to separate native or denatured proteins by the length of the polypeptide (denaturing conditions) or by the 3-D structure of the protein (native / non-denaturing conditions). The proteins are then transferred to a membrane (typically nitrocellulose or PVDF), where they are probed (detected) using antibodies specific to the target protein.

[0162] Samples may be taken from whole tissue or from cell culture. In most cases, solid tissues are first broken down mechanically using a blender (for larger sample volumes), using a homogenizer (smaller volumes), microfluidizer, or by sonication. Cells may also be broken open by one or a combination of the above mechanical methods. Assorted detergents, salts, and buffers may be employed to encourage lysis of cells and to solubilize proteins. Protease and phosphatase inhibitors are often added to prevent the digestion of the sample by its own enzymes. DNAse is also often added to improve sample clarity. Tissue preparation is often done at cold temperatures to avoid protein denaturing.

[0163] The proteins of the sample are separated using gel electrophoresis. Separation of proteins may be by isoelectric point (pl), molecular weight, electric charge, or a combination of these factors. The nature of the separation depends on the treatment of the sample and the nature of the gel. This is a very useful way to determine a protein. It is also possible to use a two-dimensional (2-D) gel which spreads the proteins from a single sample out in two dimensions. Proteins are separated according to isoelectric point (pH at which they have neutral504922-1531-8179, v. 1net charge) in the first dimension, and according to their molecular weight in the second dimension.

[0164] In order to make the proteins accessible to antibody detection, they are moved from within the gel onto a membrane made of nitrocellulose or polyvinylidene difluoride (PVDF). The membrane is placed on top of the gel, and a stack of filter papers placed on top of that. The entire stack is placed in a buffer solution which moves up the paper by capillary action, bringing the proteins with it. Another method for transferring the proteins is called electroblotting and uses an electric current to pull proteins from the gel into the PVDF or nitrocellulose membrane. The proteins move from within the gel onto the membrane while maintaining the organization they had within the gel. As a result of this blotting process, the proteins are exposed on a thin surface layer for detection (see below). Both varieties of membrane are chosen for their non-specific protein binding properties (i.e., binds all proteins equally well). Protein binding is based upon hydrophobic interactions, as well as charged interactions between the membrane and protein. Nitrocellulose membranes are cheaper than PVDF, but are far more fragile and do not stand up well to repeated probing. The uniformity and overall effectiveness of transfer of protein from the gel to the membrane can be checked by staining the membrane with Coomassie Brilliant Blue or Ponceau S dyes. Once transferred, proteins are detected using labeled primary antibodies, or unlabeled primary antibodies followed by indirect detection using labeled protein A or secondary labeled antibodies binding to the Fc region of the primary antibodies.C. Immunohistochemistry

[0165] The antibodies of the present disclosure may also be used in conjunction with both fresh-frozen and / or formalin-fixed, paraffin-embedded tissue blocks prepared for study by immunohistochemistry (IHC). The method of preparing tissue blocks from these particulate specimens has been successfully used in previous IHC studies of various prognostic factors, and is well known to those of skill in the art (Brown et al., 1990; Abbondanzo et al., 1990; Allred et al., 1990).

[0166] Briefly, frozen-sections may be prepared by rehydrating 50 ng of frozen “pulverized” tissue at room temperature in phosphate buffered saline (PBS) in small plastic capsules; pelleting the particles by centrifugation; resuspending them in a viscous embedding medium (OCT); inverting the capsule and / or pelleting again by centrifugation; snap-freezing in -70°C isopentane; cutting the plastic capsule and / or removing the frozen cylinder of tissue;514922-1531-8179, v. 1securing the tissue cylinder on a cryostat microtome chuck; and / or cutting 25-50 serial sections from the capsule. Alternatively, whole frozen tissue samples may be used for serial section cuttings.

[0167] Permanent-sections may be prepared by a similar method involving rehydration of the 50 mg sample in a plastic microfuge tube; pelleting; resuspending in 10% formalin for 4 hours fixation; washing / pelleting; resuspending in warm 2.5% agar; pelleting; cooling in ice water to harden the agar; removing the tissue / agar block from the tube; infiltrating and / or embedding the block in paraffin; and / or cutting up to 50 serial permanent sections. Again, whole tissue samples may be substituted.D. Immunodetection Kits

[0168] In still further embodiments, the present disclosure concerns immunodetection kits for use with the immunodetection methods described above. As the antibodies may be used to detect MPXV OPG153 protein, the antibodies may be included in the kit. The immunodetection kits will thus comprise, in suitable container means, a first antibody that binds to an MPXV OPG153 protein, and optionally an immunodetection reagent.

[0169] In certain embodiments, the antibody may be pre-bound to a solid support, such as a column matrix and / or well of a microtitre plate. The immunodetection reagents of the kit may take any one of a variety of forms, including those detectable labels that are associated with or linked to the given antibody. Detectable labels that are associated with or attached to a secondary binding ligand are also contemplated. Exemplary secondary ligands are those secondary antibodies that have binding affinity for the first antibody.

[0170] Further suitable immunodetection reagents for use in the present kits include the two-component reagent that comprises a secondary antibody that has binding affinity for the first antibody, along with a third antibody that has binding affinity for the second antibody, the third antibody being linked to a detectable label. As noted above, a number of exemplary labels are known in the art and all such labels may be employed in connection with the present disclosure.

[0171] The kits may further comprise a suitably aliquoted composition of MPXV OPG153 protein, whether labeled or unlabeled, as may be used to prepare a standard curve for a detection assay. The kits may contain antibody-label conjugates either in fully conjugated524922-1531-8179, v. 1form, in the form of intermediates, or as separate moieties to be conjugated by the user of the kit. The components of the kits may be packaged either in aqueous media or in lyophilized form.

[0172] The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which the antibody may be placed, or preferably, suitably aliquoted. The kits of the present disclosure will also typically include a means for containing the antibody, antigen, and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow-molded plastic containers into which the desired vials are retained.E. Flow Cytometry and FACS

[0173] The antibodies of the present disclosure may also be used in flow cytometry or FACS. Flow cytometry is a laser- or impedance-based technology employed in many detection assays, including cell counting, cell sorting, biomarker detection and protein engineering. The technology suspends cells in a stream of fluid and passing them through an electronic detection apparatus, which allows simultaneous multiparametric analysis of the physical and chemical characteristics of up to thousands of particles per second. Flow cytometry is routinely used in the diagnosis of disorders, especially blood cancers, but has many other applications in basic research, clinical practice and clinical trials.

[0174] Fluorescence-activated cell sorting (FACS) is a specialized type of cytometry. It provides a method for sorting a heterogenous mixture of biological cells into two or more containers, one cell at a time, based on the specific light scattering and fluorescent characteristics of each cell. In general, the technology involves a cell suspension entrained in the center of a narrow, rapidly flowing stream of liquid. The flow is arranged so that there is a large separation between cells relative to their diameter. A vibrating mechanism causes the stream of cells to break into individual droplets. Just before the stream breaks into droplets, the flow passes through a fluorescence measuring station where the fluorescence of each cell is measured. An electrical charging ring is placed just at the point where the stream breaks into droplets. A charge is placed on the ring based immediately prior to fluorescence intensity being measured, and the opposite charge is trapped on the droplet as it breaks form the stream. The charged droplets then fall through an electrostatic deflection system that diverts droplets into containers based upon their charge.534922-1531-8179, v. 1

[0175] In certain embodiments, to be used in flow cytometry or FACS, the antibodies of the present disclosure are labeled with fluorophores and then allowed to bind to the cells of interest, which are analyzed in a flow cytometer or sorted by a FACS machine.

[0176] Samples are taken from whole tissue or from cell culture. Solid tissues are first broken down to single cell suspension mechanically using forceps, scalpels, scissors or tissue grinders depending on the tissue source. Additional enzymatic digestion can be used to break down extracellular matrix components. Collagenase, DNAse and trypsin are often added to dislodge single cells.

[0177] In one exemplary flow cytometry analysis, the cell surface is contacted with the anti-MPXV OPG153 protein antibodies of the disclosure. After binding and washing to remove non-specifically bound immune complexes, the bound anti-MPXV OPG153 protein antibodies are detected. Where the initial anti-MPXV OPG153 protein antibodies are linked to a detectable label, the immune complexes may be detected directly.

[0178] In another exemplary flow cytometry analysis, the cell surface is contacted with the anti-MPXV OPG153 protein antibodies of the disclosure. After binding and washing to remove non-specifically bound immune complexes, detection may be achieved by the addition of a secondary antibody that has binding affinity for the primary antibody, with the secondary antibody being linked to a detectable label.

[0179] Irrespective of the format employed, flow cytometry or FACS analyses have certain features in common, such as, incubating and binding, washing to remove non-specifically bound species, and detecting the labeled immune complexes. These are described below.

[0180] In flow cytometry or FACS analyses, it is probably more customary to use a primary antibody detection means rather than a secondary procedure. Thus, after binding of a protein, and washing to remove unbound material, detection may be achieved directly where the initial anti-MPXV OPG153 protein antibodies are linked to a detectable label.

[0181] “Under conditions effective to allow immune complex (antigen / antibody) formation” means that the conditions preferably include diluting the antigens and / or antibodies with solutions such as phosphate-buffered saline (PBS), supplemented with a protein such as544922-1531-8179, v. 1bovine serum albumin (BSA) or fetal bovine serum (FBS) and Fc block to minimize nonspecific binding of antibodies to Fc receptors on cells.

[0182] The “suitable” conditions also mean that the incubation is at a temperature or for a period sufficient to allow effective binding. Incubation steps are typically from about 30 minutes to 1 hour or so, at temperatures preferably on the order of 25°C to 27°C, or may be longer, if necessary, at about 4°C or so.

[0183] Following all incubation steps in a flow cytometry or FACS analyses, the samples are washed to remove any non-complexed material. This washing step is generally performed by centrifugation to pellet the cells, followed by resuspension in a wash buffer, such as PBS or PBS containing Tween-20. The wash is typically repeated 2-3 times to ensure the removal of any nonspecific binding components and excess reagents.

[0184] For the detection of the labeled immune complex, the sample is subjected to flow cytometric analysis or FACS. The flow cytometer uses a laser to excite the fluorochrome, and the emitted fluorescence is captured and analyzed by detectors, providing data on the number of cells or particles that bind to the specific antibody or reagent, as well as the intensity of the fluorescence, which correlates with the level of MPXV OPG153 protein expression. VII. Definitions

[0185] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the use of “or” means “and / or” unless stated otherwise. Furthermore, the use of the term “including”, as well as other forms, such as “includes” and “included”, is not limiting. Also, terms such as “element” or “component” encompass both elements and components comprising one unit and elements and components that comprise more than one subunit unless specifically stated otherwise. Also, the use of the term “portion” can include part of a moiety or the entire moiety.

[0186] As used herein, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. As used herein the specification, “a” or “an” may mean one or more. As used herein in the claim(s), when used in conjunction with the word “comprising,” the words “a” or “an” may mean one or more than one.554922-1531-8179, v. 1

[0187] The term “about” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of up to ±10% from the specified value. Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the disclosed subject matter. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.

[0188] As used herein, “essentially free,” in terms of a specified component, is used herein to mean that none of the specified component has been purposefully formulated into a composition and / or is present only as a contaminant or in trace amounts. The total amount of the specified component resulting from any unintended contamination of a composition is therefore well below 0.05%, preferably below 0.01 %. Most preferred is a composition in which no amount of the specified component can be detected with standard analytical methods.

[0189] The term “antibody” refers to an intact immunoglobulin of any isotype, or a fragment thereof that can compete with the intact antibody for specific binding to the target antigen, and includes, for instance, chimeric, humanized, fully human, and bispecific antibodies. An “antibody” is a species of an antigen binding protein. An intact antibody will generally comprise at least two full-length heavy chains and two full-length light chains, but in some instances can include fewer chains such as antibodies naturally occurring in camelids which can comprise only heavy chains. Antibodies can be derived solely from a single source, or can be “chimeric,” that is, different portions of the antibody can be derived from two different antibodies as described further below. The antigen binding proteins, antibodies, or binding fragments can be produced in hybridomas, by recombinant DNA techniques, or by564922-1531-8179, v. 1enzymatic or chemical cleavage of intact antibodies. Unless otherwise indicated, the term “antibody” includes, in addition to antibodies comprising two full-length heavy chains and two full-length light chains, derivatives, variants, fragments, and muteins thereof, examples of which are described below. Furthermore, unless explicitly excluded, antibodies include monoclonal antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as “antibody mimetics”), chimeric antibodies, humanized antibodies, human antibodies, antibody fusions (sometimes referred to herein as “antibody conjugates”), and fragments thereof, respectively.

[0190] An antibody that “specifically binds to” or is “specific for” a particular polypeptide or an epitope on a particular polypeptide is one that binds to that particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope. For example, the MPXV OPG153 protein specific antibodies of the present disclosure are specific to MPXV OPG153 protein. The antibody that binds to MPXV OPG153 protein may have a dissociation constant (Kd) of ^=100 nM, ^10 nM, 1=1 nM, ^0.1 nM, ^=0.01 nM, or ^0.001 nM (e.g., 10“8M or less, e.g., from 10“8M to 10“13M, e.g., from 10-9M to 10-13M).

[0191] The term “epitope” as used herein refers to the specific group of atoms or amino acids on an antigen to which an antibody binds. The epitope can be either linear epitope or a conformational epitope. A linear epitope is formed by a continuous sequence of amino acids from the antigen and interacts with an antibody based on their primary structure. A conformational epitope, on the other hand, is composed of discontinuous sections of the antigen’s amino acid sequence and interacts with the antibody based on the 3D structure of the antigen. In general, an epitope is approximately five or six amino acids in length. Two antibodies may bind the same epitope within an antigen if they exhibit competitive binding for the antigen.

[0192] The term “identity” refers to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and comparing the sequences. “Percent identity” means the percent of identical residues between the amino acids or nucleotides in the compared molecules and is calculated based on the size of the smallest of the molecules being compared. For these calculations, gaps in alignments (if any) are preferably addressed by a particular mathematical model or computer program (i.e., an “algorithm”). Methods that can be used to calculate the identity of the aligned574922-1531-8179, v. 1nucleic acids or polypeptides include those described in Computational Molecular Biology, (Lesk, A. M., ed.), 1988, New York: Oxford University Press; Biocomputing Informatics and Genome Projects, (Smith, D. W., ed.), 1993, New York: Academic Press; Computer Analysis of Sequence Data, Part I, (Griffin, A. M., and Griffin, H. G., eds.), 1994, New Jersey: Humana Press; von Heinje, G., 1987, Sequence Analysis in Molecular Biology, New York: Academic Press; Sequence Analysis Primer, (Gribskov, M. and Devereux, J., eds.), 1991, New York: M. Stockton Press; and Carillo et al., 1988, SIAM J. Applied Math. 48:1073.

[0193] In calculating percent identity, the sequences being compared are typically aligned in a way that gives the largest match between the sequences. One example of a computer program that can be used to determine percent identity is the GCG program package, which includes GAP (Devereux et al., 1984, Nucl. Acid Res. 12:387; Genetics Computer Group, University of Wisconsin, Madison, Wis.). The computer algorithm GAP is used to align the two polypeptides or polynucleotides for which the percent sequence identity is to be determined. The sequences are aligned for optimal matching of their respective amino acid or nucleotide (the “matched span”, as determined by the algorithm). A gap opening penalty (which is calculated as 3x the average diagonal, wherein the “average diagonal” is the average of the diagonal of the comparison matrix being used; the “diagonal” is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1 / 10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. A standard comparison matrix (see, Dayhoff et al., 1978, Atlas of Protein Sequence and Structure 5:345-352 for the PAM 250 comparison matrix; Henikoff etal., 1992, Proc. Natl. Acad. Sci. U. S. A. 89:10915-10919 for the BLOSUM 62 comparison matrix) may be also used by the algorithm.

[0194] Examples of parameters that can be employed in determining percent identity for polypeptides or nucleotide sequences using the GAP program can be found in Needleman etal., 1970, J. Mol. Biol. 48:443-453.

[0195] Certain alignment schemes for aligning two amino acid sequences may result in matching of only a short region of the two sequences, and this small aligned region may have very high sequence identity even though there is no significant relationship between the two full-length sequences. Accordingly, the selected alignment method (GAP program) can be584922-1531-8179, v. 1adjusted if so desired to result in an alignment that spans at least 50 or other number of contiguous amino acids of the target polypeptide.

[0196] The term “link” as used herein refers to the association via intramolecular interaction, e.g., covalent bonds, metallic bonds, and / or ionic bonding, or inter-molecular interaction, e.g., hydrogen bond or noncovalent bonds.

[0197] The term “operably linked” refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, a given signal peptide that is operably linked to a polypeptide directs the secretion of the polypeptide from a cell. In the case of a promoter, a promoter that is operably linked to a coding sequence will direct the expression of the coding sequence. The promoter or other control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. For example, intervening untranslated yet transcribed sequences can be present between the promoter sequence and the coding sequence and the promoter sequence can still be considered “operably linked” to the coding sequence.

[0198] The use of the term “or” in the claims is used to mean “and / or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and / or.” As used herein “another” may mean at least a second or more.

[0199] The term “polynucleotide” or “nucleic acid” includes both single-stranded and double-stranded nucleotide polymers. The nucleotides comprising the polynucleotide can be ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide. Said modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2',3'-dideoxyribose, and intemucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phoshoraniladate and phosphoroamidate.

[0200] The terms “polypeptide” or “protein” means a macromolecule having the amino acid sequence of a native protein, that is, a protein produced by a naturally-occurring and nonrecombinant cell; or it is produced by a genetically-engineered or recombinant cell, and comprise molecules having the amino acid sequence of the native protein, or molecules having deletions from, additions to, and / or substitutions of one or more amino acids of the native sequence. The term also includes amino acid polymers in which one or more amino acids are594922-1531-8179, v. 1chemical analogs of a corresponding naturally occurring amino acid and polymers. The terms “polypeptide” and “protein” specifically encompass MPXV OPG153 protein binding proteins, antibodies, or sequences that have deletions from, additions to, and / or substitutions of one or more amino acid of antigen-binding protein. The term “polypeptide fragment” refers to a polypeptide that has an amino-terminal deletion, a carboxyl-terminal deletion, and / or an internal deletion as compared with the full-length native protein. Such fragments can also contain modified amino acids as compared with the native protein. Fragments may be about five to 500 amino acids long. For example, fragments can be at least 5, 6, 8, 10, 14, 20, 50, 70, 100, 110, 150, 200, 250, 300, 350, 400, or 450 amino acids long. Useful polypeptide fragments include immunologically functional fragments of antibodies, including binding domains. In the case of an MPXV OPG153 protein-binding antibody, useful fragments include but are not limited to a CDR region, a variable domain of a heavy and / or light chain, a portion of an antibody chain or just its variable region including two CDRs, and the like.

[0201] The pharmaceutically acceptable carriers are conventional. Remington’s Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of the fusion proteins herein disclosed. In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (e.g., powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch or magnesium stearate. In addition to biologically- neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.

[0202] As used herein, the term “subject” refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cattle, swine, sheep, horse or primate). A human includes pre-and post-natal forms. A subject may be a human being. A subject can be a patient, which refers to a human presenting to a medical provider for diagnosis or treatment of a disease. The term “subject” is used herein interchangeably with “individual” or “patient.” A subject can be604922-1531-8179, v. 1afflicted with or is susceptible to a disease or disorder but may or may not display symptoms of the disease or disorder.

[0203] The term “therapeutically effective amount” or “effective dosage” as used herein refers to the dosage or concentration of a drug effective to treat a disease or condition. For example, with regard to the use of the monoclonal antibodies or antigen-binding fragments thereof disclosed herein to treat viral infection.

[0204] “Treating” or “treatment” of a condition or infection as used herein includes preventing or alleviating a condition or infection, slowing the onset or rate of development of a condition or infection, reducing the risk of developing a condition or infection, preventing or delaying the development of symptoms associated with a condition or infection, reducing or ending symptoms associated with a condition or infection, generating a complete or partial regression of a condition or infection, mitigating a condition or infection, curing a condition or infection, or some combination thereof.

[0205] “Prevention” or “preventing” includes: (1) inhibiting the onset of a disease / infection in a subject or patient which may be at risk and / or predisposed to the disease / infection but does not yet experience or display any or all of the pathology or symptomatology of the disease / infection, and / or (2) slowing the onset of the pathology or symptomatology of a disease / infection in a subject or patient which may be at risk and / or predisposed to the disease / infection but does not yet experience or display any or all of the pathology or symptomatology of the disease / infection.

[0206] As used herein, a “vector” refers to a nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell. A vector may include nucleic acid sequences that permit it to replicate in the host cell, such as an origin of replication. A vector may also include one or more therapeutic genes and / or selectable marker genes and other genetic elements known in the art. A vector can transduce, transform or infect a cell, thereby causing the cell to express nucleic acids and / or proteins other than those native to the cell. A vector optionally includes materials to aid in achieving entry of the nucleic acid into the cell, such as a viral particle, liposome, protein coating or the like.614922-1531-8179, v. 1VIII. Examples

[0207] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.Example 1 - Identification of OPG153 as a target of MPXV-neutralizing antibodies MPXV is a large, double-stranded DNA vims within the Orthopoxvirus genus of the Poxviridae family and is genetically related to variola (VARV), vaccinia (VACV), and cowpox (CPXV) viruses (MacNeill, 2022). These are among the most complex human viruses known, encoding for more than 200 gene products (Shchelkunov et al., 2002). Orthopoxviruses exist in two antigenically distinct virion forms: the intracellular mature virion (MV) and the extracellular enveloped virion (EV) (McFadden, 2005). Prior studies identified several orthopoxvirus proteins targeted by neutralizing monoclonal antibodies (nAbs), including MV proteins encoded by Orthopoxvirus genes (OPG) (Senkevich et al., 2021) 95 (MPXV Ml; VACV LI) (Wolffe et al., 1995; Ren et al., 2024), 108 (MPXV and VACV H3), 120 (MPXV E8; VACV D8), 154 (MPXV A29; VACV A27) (Lai et al., 1991; Zhu et al., 2024), 155 (MPXV A30; VACV A28), and EV proteins OPG161 (MPXV A35; VACV A33) and OPG190 (MPXV B6; VACV B5) (Ren et al., 2024; Zhao et al., 2024; Aldaz-Carroll et al., 2005; Li et al., 2023; Riccardo & Pablo, 2023). Antibodies targeting these proteins neutralize the corresponding virion forms (Shchelkunov et al., 2002). These observations guided the design of new vaccines, which demonstrated that immunization with a combination of antigens from both MV and EV provides enhanced protection compared to monovalent formulations (Lustig et al., 2005; Putz et al., 2006). Despite ongoing efforts, MPXV continues to spread globally, underscoring the urgent need for novel immunotherapeutics and vaccine candidates. To address this, the inventors synergistically combined Reverse Vaccinology 2.0, AlphaFold 3-based predictive modeling, and electron microscopy to agnostically isolate and characterize neutralizing monoclonal antibodies (nAbs) from MPXV -infected or MVA-BN-vaccinated individuals, identify their antigenic target, and design an effective monovalent vaccine candidate.624922-1531-8179, v. 1

[0208] MPXV has >35 annotated surface-exposed proteins, most of which have unknown structures or functions. Therefore, to narrow the pool of potential targets of the nAbs isolated from donor samples, pairwise interactions with MPXV full-length envelope proteins were screened. High-confidence interactions between OPG153 (MPXV A28; VACV A26) and nAbs 08E11 and 12112 were predicted. OPG153 plays multifaceted roles in orthopoxvirus biology, with evidence suggesting OPG153 mediates (i) host interaction (Chiu et al., 2007), (ii) A-type inclusion body formation (Howard et al., 2010; McKelvey et al., 2002), (iii) EV generation (Howard et al., 2008; Ulaeto et al., 1996), and (iv) cell entry (Chang et al., 2010; Chang et al., 2012). Its association with the viral membrane is mediated by a heterotrimeric, C -terminal, disulfide -bonded, coiled-coil interaction with OPG154 (MPXV A29; VACV A27) (Howard et al., 2008; Chang et al., 2013). OPG153 has been reported to associate exclusively with the MV form of VACV (Ulaeto et al., 1996), highlighting the need for further investigations into differences in surface antigen presentation between MV and EV forms. Notably, nAbs targeting OPG153 have not yet been isolated. Both 08E11 and 12112 were predicted to interact with the N-terminal globular domain of OPG153 (FIG. 1), recognizing non-overlapping epitopes.

[0209] Based on the AlphaFold 3 structural predictions identifying OPG153 as a potential target of nAbs, the globular domain (residues 1-366) of MPXV OPG153 was expressed and purified with the native N terminus and a C-terminal affinity tag (FIG. 1). OPG153 does not possess a signal peptide, yet it was able to be purified from the supernatant of transiently transfected FreeStyle 293-F cells (FIG. 2). Surface plasmon resonance (SPR) experiments showed high-affinity binding of Fabs 08E11 and 12112 to MPXV OPG153, with Xbs of 18.5 nM and 3.2 nM, respectively (FIG. 3). These binding results validated the prediction that OPG153 is a target of MPX V-neutralizing antibodies.

[0210] A flow cytometry-based assay was performed to assess the binding of 12 MPXV nAbs to OPG153. In addition to 08E11 and 12112. six more nAbs (02N10. 02M12, 04B17, 08H03, 09002, and 16C15) bound to the OPG153 globular N-terminal domain. These six additional antibodies had low-confidence interactions with OPG153 as modeled by AlphaFold 3, indicating that false-negatives will occur with this in silico screening procedure. Consequently, biolayer interferometry analysis was performed to assess binding between the remaining four nAbs with unknown targets (01G09, 04M05, 13B1I, and I3DI5) and the634922-1531-8179, v. 1ectodomains of known orthopoxvirus neutralizing targets OPG95, OPG 108, OPG120, OPG154, OPG161, and OPG191, but no interactions were observed (FIG. 3B).

[0211] Given the high sequence conservation of OPG 153 among orthopoxviruses (>93% identity), cross-reactivity to the OPG153 orthologs from VACV, CPXV, and VARV were further evaluated. All MPXV OPG153-reactive nAbs bound the VACV and CPXV OPG153 orthologs with the exception of 12112, which did not interact with VACV OPG153 (FIG. 4A, left). These data are consistent with the observed lack of VACV neutralization by 12112. Similarly, all MPXV OPG 153 -binding antibodies, except 08E11, interacted with OPG153 of VARY. Four antibodies (01G09, 04MO5, 13B11, and 13015) did not bind any of the tested OPG 153 orthologs and are presumed to target distinct, unidentified MPXV antigens. To evaluate whether the OPG153-binding antibodies recognized overlapping or distinct epitopes, competition assays were conducted using labeled 08E11 and 12112 as competitors, which were chosen due to their different binding and neutralization profiles, Based on binding¬ interference patterns, antibodies were classified into four competition groups. Group I antibodies (02N10, 04B17, 08E11, and 16C15) competed with 08E11 (FIG. 4A, right). These antibodies displayed broad binding to OPG153 orthologs and potent neutralization across MPXV clades and virion forms, as well as VACV. Group II antibodies (08H03 and 09002) competed with both 08E11 and 12112 and shared the same binding and neutralization profiles as Group I antibodies. Group II nAb 09002 is the only OPG153-targeting antibody isolated that stimulated Fc-effector functions. Group III antibody 12112 competed with itself but not with 08E11 and did not neutralize VACV or MPXV EV (FIG. 4A, right). Group IV antibody 02M12 did not compete with any other antibody, suggesting it targets a distinct epitope on OPG 153. though SPR showed it too bound with high affinity (X’DS = 30.7 nM) to OPG 153 (FIG. 3). Despite its broad OPG153 reactivity, 02M12 exhibited lower neutralization breadth, with no activity against VACV or MPXV-IIb EV.

[0212] To validate the predicted interactions between the MPXV-nAbs and OPG153, cryo-electron microscopy (cryo- EM) analyses were conducted. Guided by the binding studies, a ternary complex of OPG153 N-terminal domain with Fabs 08E11 and 12112 and a binary complex of OPG153 with Fab 02M12 were assembled. Two datasets comprising 891 movies at 0° and 1,147 movies at 30° tilt were acquired for the ternary complex OPG153-08E11-12112 using a 200 kV Glacios microscope and merged for processing. A total of 186,643 particles were selected for final reconstruction, yielding a 2.8 A resolution map. For the binary complex644922-1531-8179, v. 1OPG153-02M12, 1,743 movies were collected, resulting in 132,110 final particles that yielded a 3.2 A resolution map. Neither EM map showed detectable N-acetylglucosamine density at the three putative N-X-S / T glycosylation sequons (residues 194, 320, and 351 ), consistent with the absence of a signal peptide in MPXV OPG153. The refined structures of the MPXV OPG153 N-terminal domains agree well with the AlphaFold 3 prediction and with a 1.2 A resolution crystal structure of the VACV ortholog (R. M. S. D. = 0.5 A for both structures) (Chang et al., 2019).

[0213] The cryo-EM map and model of the OPG153-08E11-12112 complex reveal two adjacent but non-overlapping epitopes within the globular a-helical domain of MPXV OPG 153 AlphaFold 3 predictions (FIGS. 4B, 4C). Fab 08E11 binding to OPG153 is mediated predominantly by its heavy chain, which buries 801 A2on the OPG153 surface. H-CDR2 makes the most contacts of the CDR loops, interacting mainly with a helix (a)7 and residues 156-167 within the a8 helix (Chang et al., 2019). The 08E11 light chain buries a more modest 315 A2of surface area on OPG153, with interactions primarily involving L-CDR1 and L- CDR3, contacting helices a4 and a5 and the linker between a6 and a7 (FIGS. 4B. inset ii, and 7). Interacting residues (<5 A) between OPG153 and 08E11 are highly conserved among pathogenic orthopoxviruses, with the exception of 4 positions (FIG. 7). Of these, substitutions H92Y, D136N, and / or R205G in VARV could be responsible for the abolished binding of 08E1 1 to VARV OPG153 (FIGS. 4A and 7).

[0214] The 12112 heavy chain buries a total surface area of 452 A2on the OPG153 globular domain (FIGS. 4B, inset Hi, and 7). All three heavy chain CDR loops interact with OPG153, with H-CDR2 contributing the most contacts. Notably, the 12112 H-CDR3 residue Arg99 extends into the interface between all three proteins in the complex, establishing a salt bridge with OPG153 Aspl56. The 12112 light chain CDRs bury only 249 A2on the OPG153 surface, interacting with the N terminus of OPG153 al 0 and the al 3 helix. The epitope targeted by 12112 is less conserved among pathogenic orthopoxviruses than that of 08E11, particularly in alO and al 1 (FIG. 7). Ammo-acid differences between MPXV and VACV OPG153 at ~30% of the interacting residues (positions 156, 197, 201, 207, and 235) could explain the lack of 12112 binding or neutralization of VACV (FIGS. 3A and 7).

[0215] 02M12 buries a total of 876 A2of surface area on the [3-sandwich domain of OPG153, distal to the 08E11 and 12112 binding sites (FIGS. 4B, 4C). This interaction wras not predicted by AlphaFold 3, even after additional screening using multiple seeds and diffusion654922-1531-8179, v. 1samples. The experimentally determined interaction is predominantly mediated by 02M12 heavy-chain contacts with the loop of OPG153 between [3-strands (P)5 and 6 (residues 295-305) (FIG. 4B, inset iv). Arg97 of H-CDR3 hydrogen bonds to Asn295 at the N terminus of the OPG153 loop, while adjacent H-CDR3 residue Tyr98 reaches in the opposite direction to interact with OPG153 Glu304. Residues 99-100A of H-CDR3 establish a series of antiparallel backbone interactions with OPG153 residues 299-303, while the sidechain of H-CDR3 TyrlOO also hydrogen bonds with the backbone of OPG153 Lys296. Light-chain contacts bury 277 A2of surface area on OPG153 and include Trp35 — positioned C-terminal to L-CDR1 — interacting with OPG153 Glu270 on 3. The epitope targeted by 02M12 is generally well conserved among pathogenic orthopoxviruses, with variation at only two positions (FIG. 7). Though 02M12 was unable to neutralize VACV, its binding to whole virus and purified OPG153 was similar between MPXV and VACV (FIGS. 3A and 4A).

[0216] The reduced neutralization potency of 02M12 relative to 08E11 and 12112 may indicate that the -sandwich domain targeted by 02M12 is less neutralization-sensitive than the a-helical domain targeted by 08E11 and 12112. This could imply that the a-helical domain may be more important for the function of OPG153, or that this domain is more accessible on the virion surface. More specifically, these structures, combined with our epitope binning analysis, suggest that antibodies targeting the 08E11 epitope (Group-I and -II) on or near a4-a8 are potentially more susceptible to neutralization on the orthopoxvirus virion. This could suggest the importance of this epitope to OPG153 function, which is further supported by its evolutionary conservation.

[0217] The identification of OPG153 as a major target of MPXV -neutralizing antibodies prompted the evaluation of the frequency of OPG153-specific MBCs in all infected and vaccinated individuals enrolled in this study. PBMCs were stained with Alexa Fluor 488-labeled recombinant MPXV OPG153 and analyzed by flow cytometry to detect CDl91CD27’IgD IgM OPG153' MBCs. Antigen-specific MBCs were detected in all donor samples. However, MPXV-infected donors exhibited a 2.2-fold higher frequency of OPG153- specific MBCs than MVA-BN-vaccinated individuals, suggesting that natural infection elicits a quantitatively more abundant response against this antigen or that the responses to MVA-BN antigens are lower overall.664922-1531-8179, v. 1Example 2 - Immunization with OPG153 induces cross-poxvirus neutralizing antibodies

[0218] To evaluate the immunogenicity of OPG153, 7-8-week-old BALB / c mice were immunized intramuscularly with 10 g of MPXV-Ib OPG153 globular domain emulsified in 25 pL of MF59-like adjuvant (AddaVax). This group was compared to mice immunized with 50 pL of MVA-BN vaccine (infection units ranging from 0.5 to 3.95 x 107) or 10 pg of severe acute respirtaroy syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein plus AddaVax (FIG. 5 A). Each group consisted of 10 mice. Immunizations were administered on days 0 and 21, and serum samples were collected two weeks post-second dose (day 35). Neutralization antibody titers were assessed against MPXV-IIb containing both forms of the vims, MPX V-11b MV, MPXV-IIb EV and VACV (FIGS. 5B, 5C). Neutralization titers were reported as 100% inhibitory dilution (IDioo) for MPXV and as 50% inhibitory dilution (ID50) for VACV. As expected, sera from mice immunized with the S protein exhibited no neutralizating activity against MPXV-IIb or VACV. Conversely, OPG153 immunization elicited robust MPXV-IIb serum neutralization titers (median IDioo = 2,240). which were significantly higher than MVA- BN immunization (median IDioo = 280) (FIG. 5B, left). Compared to MVA-BN, immunization with OPG153 induced higher titers against MV but lower titers against EV (FIG. 5B, middle and right). These findings suggest that surface exposure and availability of OPG153 may differ between the two viral forms. Finally, immunization with OPG153 elicited significantly higher neutralization titers against VACV (median TD50 = 5,1 0) compared to MVA-BN (median ID50 - 960) and S protein groups, highlighting the potential of OPG153 to induce cross-poxvirus neutralizing antibodies (FIG. 5C).Example 3 - Material and Methods

[0219] Expression and purification of MPXV OPG153 globular domain. FreeStyle 293-F cells (ThermoFisher) were cultured in FreeStyle 293 expression medium (Gibco) at 37 °C in a shaker incubator with 8% CO2 and 80% humidity. For passaging, cells were seeded at a density of 0.3 x 106cells / mL. Codon-optimized (GenScript) sequences for MPXV [NCBI Reference Sequence: NP_536565.1], VACV [NCBI Reference Sequence: NC_006998.1], and CPXV OPG153 [GenBank: X94355.2] (residues 1-366) were cloned into the mammalian expression vector paH, upstream of a human rhinovirus 3C (HRV3C) protease cleavage site, an 8 x His tag, and a Twin-Strep tag. The OPG153 plasmids were transiently transfected into FreeStyle 293-F cells at a density of 1 x 106cells / mL using 25 kDa linear polyethylenimine (PEI) at a 3:1 PEEDNA ratio, with a final concentration of 0.1% Pluronic Acid F-68 (MP674922-1531-8179, v. 1Biomedicals). Cells were cultured for 5-6 days at 37 °C in a shaker incubator with 8% CO2 and 80% humidity. Culture supernatant was collected by centrifugation and filtered (0.22 pm) before being purified using Strep-Tactin XT 4Flow resin, following the manufacturer’s instructions (IBA). The elution fraction was concentrated to <500 pL and further purified via a Superdex 200 Increase 10 / 300 GL column (Cytiva) equilibrated in PBS. Protein-containing fractions were concentrated, flash-frozen, and stored at -70 °C.

[0220] Cryo-EM sample preparation. The MPXV OPG153 globular domain protein was diluted to a final concentration of 0.28 mg / mL (OPG153-08E11-12112) or 0.22 mg / mL (OPG153-02M12) and pre-incubated with a 1.2-fold molar excess of 08E11 Fab and an equimolar amount of 12112 Fab (OPG153-08E11—12112) or an equimolar amount of 02M12 (OPG153-02M12) in 20 mM Tris (pH 8.0), 200 mM NaCl for 30 min at room temperature. Amphipol A8-35 (Anatrace, cat. #A835) was added for a final concentration of 0.02% immediately before freezing. A 3.8 pL aliquot of the mixture was applied to a 30-s glow-discharged (PELCO easiGlow™) UltrAuFoil 1.2 / 1.3 300-mesh TEM grid (Electron Microscopy Sciences, cat. #Q350AR13A). The grid was plunge-frozen in liquid ethane using a Vitrobot Mark IV (FEI) with a blot time of 9 s, blot force of 1, at 22 °C and 100% humidity.

[0221] Biolayer interferometry. Biolayer interferometry analysis was performed using a Fortebio Octet HTX (Sartorius) system at 25 °C with an orbital shaking speed of 1000 rpm and Octet® AHC2 Biosensors (Sartorius) and Octet BLI discovery (vl3.0.3.26) software. Biosensors were first equilibrated in kinetic buffer (1 x HBS-P+ with 0.1% w / v BSA; Cytiva) for 10 min before an initial 60 s baseline followed by loading by immersion in wells containing 10-50 nM IgG for 60 s, optimized for a uniform loading response of 0.6 nm. IgG-loaded tips were immersed in kinetic buffer for 60 s to establish a baseline before immersion into wells containing MPXV antigen ectodomains (0 or 300 nM) for 60 or 600 s (association, To) followed by 300 s in kinetic buffer (dissociation). Data were fit to a 1:1 binding model with doublereference subtraction using Octet Analysis Studio (vl3.0.3.52) software. Data were then transferred to GraphPad Prism (vl0.5.0) for visualization.

[0222] Cryo-EM data collection, processing, and analysis. The TEM grid was loaded onto a 200 kV Glacios (Thermo Fisher Scientific) equipped with a Falcon 4 detector. All movies were collected at a total dose of 50 e⁻ Å2under 150,000x magnification corresponding to a pixel size of 0.933 A / pix with a defocus range of -1.5 to -2.5 pm. Data collection was automated using SerialEM (Mastronarde et al., 2003). A total of 890 movies at 0° and 1,147684922-1531-8179, v. 1movies at 30° were collected for the OPG153-08E11-12112 dataset. A total of 299 movies at 0° and 1,444 movies at 30° were collected for the OPG153-02M12 dataset. Datasets were imported in CryoSPARC v4.5.3 (Punjani et al., 2017) for processing. The final maps for model building were orientation-rebalanced and sharpened using DeepEMhancer (Sanchez-Garcia et al., 2021). The AlphaFold 3-predicted models were used as a starting point for model building. Iterative refinement was performed using Phenix 1.21.2-5419 real-space refinement (Liebschner et al., 2019; Afonine et al., 2018), Coot 0.9.8.95 EL (CCP4) (Emsley et al., 2010), and UCSF ChimeraX-1.9 ISOLDE (Croll et al., 2018). Total buried solvent accessible surface area was calculated with PDBePISA (Krissinel et al., 2007).

[0223] Production of hyperimmune serum in immunized mice. Three groups of ten female BALB / c mice (7-8 weeks on at study initiation) were immunized by intramuscular (IM) injection on days 0 and 21. Each mouse was immunized with 10 pg of recombinant protein — either OPG153 (residues 1-366) or SARS-CoV-2 S protein HexaPro (Hsieh et al., 2020) — formulated in 25 pL of AddaVax™ (Squalene-based oil-in-water adjuvant, InvivoGen) and diluted in PBS to reach a final volume of 50 pL. A third group received 50 pL of Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine. On day 35, terminal blood samples were collected via exsanguination under isofluorane anesthesia for serum processing. Sacrifice was carried out by cervical dislocation. Targeted volume for terminal blood collection was approximately 800 pL per mouse. Serum was isolated from the whole blood by centrifugation and stored in vials at -20°C until usage.

[0224] Statistical analysis. Statistical analysis was performed using GraphPad Prism Software (version 8.4.2). Statistical significance is shown as *, **, *** and **** for p values < 0.05, < 0.01, < 0.001 and < 0.0001 respectively. Significant differences between groups were evaluated using Tukey's multiple comparisons test one-way ANOVA (95% confidence interval). Serum neutralization titers are shown as Logio. Black lines denote the median values for each group. Dotted lines represent the lower limit of detection (LLD).Example 4 - MPXV OPG153 globular domain engineering

[0225] The base constructs used for the MPXV OPG153 globular domain engineering contained the amino acids 1-366 of SEQ ID NO: 1 followed by an HRV3C-8XHis-TwinStrep tag (FIG. 2A). Using structure-based design, substitutions that were aimed at favoring the expression and stability of the MPXV OPG153 globular domain were introduced into the base694922-1531-8179, v. 1construct. Pairs of core-facing residues less than 5 A apart were replaced with aromatic sidechains or pairs of aromatic and positively charged sidechains to favor pi-pi or pi-cation interactions, respectively. Alternatively, residues were replaced with extended or bulkier hydrophobic sidechains in efforts to fill pre-existing internal cavities. Disulfide bonds were designed to increase overall stability. Prolines were introduced to cap helices. The charged or polar substitutions were aimed to establish hydrogen bonds or salt bridges with the native residues that were predicted to be within 4.0 A. Exemplary substitutions and combinations of substitutions are provided in Table 1.

[0226] Plasmids encoding MPXV OPG153 globular domain variants were transiently transfected into FreeStyle293F cells (Thermo Fisher) using polyethyleneimine. Cultures were grown for 4-6 days, and culture supernatant was separated via centrifugation and passage through a 0.22 pm filter. Protein was purified from supernatants using Strep-TactinXT resin (IB A). OPG153 variants were further purified by size -exclusion chromatography (SEC) using a Superdex200 10 / 300 column (GE Healthcare) in phosphate-buffered saline. For initial purification and characterization, single substitutions and combinatorial variants were purified from 80 mL cultures. The protein purity was determined by NuPAGE gel (FIG. 6). Expression level was determined by A280. Yield data are provided in Table 3.Table 3704922-1531-8179, v. 1

[0227] Additional single substitutions, as well as combinations, were generated and tested for expression in BL21(DE3) using a pET28b vector. Forexpression, 100 mLof TB was inoculated with 1 mL of saturated culture containing the OPG153 plasmid. Cultures were grown at 37 °C until ODeoo reached 0.8-1.5, at which point cultures were induced with 0.5 mM IPTG and grown overnight at 16 °C. Cells were harvested and lysed with BugBuster Master Mix. Expression levels were determined by StrepXT, OPG153 variants were further purified by SEC using a Superdex200 10 / 300 column (GE Healthcare) in phosphate-buffered saline, and thermostability was determined by differential scanning fluorimetry (DSF). All variants were prepared at a concentration of 0.3 mg / mL with a final concentration of 3X SYPRO Orange Protein Gel Stain (Sigma-Aldrich) in a white, opaque 96-well plate. Fifteen fluorescence measurements λex = 465 nm, λem = 580 nm) were taken per °C using a Roche LightCycler 480 II. Data were plotted as the derivative of the melting curve. Each curve is an average of three technical replicates. Yield and thermostability data are provided in Table 4. DSF plots for the top designs are shown in FIG. 8. TGX Stain-Free Gels for the top combination designs are shown in FIG. 9. Combinations of the round 1 hits were well tolerated, with an ~13 °C increase in Tm over base for the K47C / N309C_N351E_G229P_D305P combo (Cl). Binding of OPG153 IgGs to the combination designs was tested by BLI and found to be very comparable to the base construct (FIG. 10).

[0228] In addition to substitution variants, C-terminal variants were also tested in Freestyle cells, and it was found that the 1-368 construct had the best expression, with ~3-fold increase over the original 1-366 (FIG. 11). All other experiments were conducted in a 1-366 construct for consistency, but the 1-368 variant may be superior for vaccine design.Table 4714922-1531-8179, v. 172 4922-1531-8179, v. 173 4922-1531-8179, v. 1* * *

[0229] All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.744922-1531-8179, v. 1REFERENCESThe following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.Afonine et aL, Real-space refinement in PHENIX for cryo-EM and crystallography. Acta crystallographica. Section D, Structural Biology 74, 531-544 (2018).Aldaz-Carroll et al., Epitope-mapping studies define two major neutralization sites on the vaccinia vims extracellular enveloped vims glycoprotein B5R. Journal of Virology 79, 6260-6271 (2005).Beiras et al., Concurrent outbreaks of mpox in Africa-an update. The Lancet 405, 86-96 (2025). Chang et al., Crystal stmcture of vaccinia viral A27 protein reveals a novel structure critical for its function and complex formation with A26 protein. PLoS Pathog 9, 31003563 (2013).Chang et al., Vaccinia mature vims fusion regulator A26 protein binds to A 16 and G9 proteins of the viral entry fusion complex and dissociates from mature virions at low pH. Journal of Virology 86, 3809-3818 (2012).Chang et al., Vaccinia viral A26 protein is a fusion suppressor of mature virus and triggers membrane fusion through conformational change at low pH. PLoS Pathogens 15, el007826 (2019).Chang et al., Vaccinia vims A25 and A26 proteins are fusion suppressors for mature virions and determine strain-specific vims entry pathways into HeLa, CHO-K1, and L cells. Journal of Virology 84, 8422-8432 (2010).Chiu et al., Vaccinia vims 4c (A26L) protein on intracellular mature vims binds to the extracellular cellular matrix laminin. J Virol 81, 2149-2157, 2007.Croll, ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallographica. Section D, Stmctural Biology 74, 519- 530 (2018).Dalton et al., Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study - United States, August 19, 2022-March 31, 2023. MMWR. Morbidity and mortality weekly report 72, 553-558 (2023).Deputy Nicholas et al., Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States. New England Journal of Medicine 388, 2434-2443 (2023).754922-1531-8179, v. 1Emsley et al., Features and development of Coot. Acta Crystallographica. Section D, Biological Crystallography 66, 486-501 (2010).Gilchuk et al., Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. Cell 167, 684-694.e9, 2016.Grabenstein & Hacker, Vaccines against mpox: MVA-BN and LC16m8. Expert Review of Vaccines 23, 796-811 (2024).Howard et al., Congregation of orthopoxvirus virions in cytoplasmic A-type inclusions is mediated by interactions of a bridging protein (A26p) with a matrix protein (ATIp) and a virion membrane-associated protein (A27p). J Virol 84, 7592-7602 (2010).Howard et al., Vaccinia vims A26 and A27 proteins form a stable complex tethered to mature virions by association with the A17 transmembrane protein. J Virol 82, 12384-12391 (2008).Hsieh et al., Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501-1505 (2020).Krissinel & Henrick, Inference of macromolecular assemblies from crystalline state. Journal of Molecular Biology 372. 774-797 (2007).Lai et al., The purified 14-kilodalton envelope protein of vaccinia vims produced in Escherichia coli induces vims immunity in animals. Journal of Virology 65, 5631-5635 (1991). Lansiaux et al.. The virology of human monkeypox vims (hMPXV): A brief overview. Vims Res 322, 198932 (2022).Li et al., The land-scape of immune response to monkeypox vims. EBioMedicine 87, 104424 (2023).Liebschner et al., Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallographica. Section D, Stmctural Biology 75, 861-877 (2019).Lin, T.-H. Wen, W.-L. Shih, S. H. Vermund, C.-T. Fang, Impact of vaccination and high-risk group awareness on the mpox epidemic in the United States, 2022-2023: a modelling study. eClinicalMedicine 68, 102407 (2024).Lustig et al., Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia vims protect mice against a lethal respiratory challenge. Journal of Virology 79, 13454-13462 (2005).MacNeill, Comparative Pathology of Zoonotic Orthopoxviruses. Pathogens (Basel, Switzerland) 11, 892 (2022).764922-1531-8179, v. 1Mastronarde, SerialEM: A Program for Automated Tilt Series Acquisition on Tecnai Microscopes Using Prediction of Specimen Position. Microscopy and Microanalysis 9, 1182-1183 (2003).McFadden, Poxvirus tropism. Nature Reviews Microbiology 3, 201-213 (2005).McKelvey et al., Identification of the orthopoxvirus p4c gene, which encodes a structural protein that directs intracellular mature vims particles into A-type inclusions. J Virol 76, 11216-11225 (2002).Moss, Understanding the biology of monkeypox vims to prevent future outbreaks. Nature Microbiology 9, 1408-1416, (2024).Mucker et al., Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates. Cell 187, 5540-5553.e5510 (2024).Phipps et al., Short-Lived Neutralizing Antibody Responses to Monkeypox Vims in Smallpox Vaccine-Naive Persons after JYNNEOS Vaccination. Emerging infectious diseases 31, 237-245 (2025).Punjani et al., cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nature Methods 14, 290-296 (2017).Putz et al., Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia vims provides a benchmark for smallpox vaccination. Nat Med 12, 1310-1315 (2006).Raccagni et al., Viral blips and virologic failures following mpox vaccination with MVA-BN among people with HIV. AIDS (London, England) 37, 2365-2369 (2023).Ren et al., Identification of mpox MIR and B6R monoclonal and bispecific antibodies that efficiently neutralize authentic mpox vims. Emerging Microbes & Infections 13, 2401931 (2024).Riccardo & Pablo, Neutralization Determinants on Poxvimses. Vimses 15, 2396 (2023). Rosenberg et al., Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection - New York, 2022. MMWR. Morbidity and Mortality Weekly Report 72, 559-563 (2023).Sanchez-Garcia et al., DeepEMhancer: a deep learning solution for cryo-EM volume postprocessing. Communications Biology 4, 874 (2021).Senkevich et al., Ancient Gene Capture and Recent Gene Loss Shape the Evolution of Orthopoxvirus-Host Interaction Genes. mBio 12, e0149521 (2021).Shchelkunov et al., Analysis of the monkeypox vims genome. Virology 297, 172-194 (2002).774922-1531-8179, v. 1Tai et al., An mRNA vaccine against monkeypox virus inhibits infection by co-activation of humoral and cellular immune responses. Nature Communications 16, 2971, 2025. Ulaeto et al., The vaccinia virus 4c and A-type inclusion proteins are specific markers for the intracellular mature vims particle. J Virol 70, 3372-3377 (1996).Wolffe et al., A myristylated membrane protein encoded by the vaccinia vims L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 211, 53-63 (1995).World Health Organization, Global Mpox Trends, https: / / web.archive. Org / web / 20250220062703 / https: / / worldhealthorg.shinyapps.io / mp x_global / (2025).World Health Organization, Multi-country outbreak of mpox, External situation report #44 - 23 December 2024.Zaeck et al., Low levels of monkeypox vims-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nature Medicine 29, 270-278 (2023).Zhao et al., Two noncompeting human neutralizing antibodies targeting MPXV B6 show protective effects against orthopoxvirus infections. Nature Communications 15, 4660 (2024).Zhu et al., The Generation and Characterization of Monoclonal Antibodies against the MPXV A29L Protein. Vimses 16, 1184 (2024).784922-1531-8179, v. 1

Claims

CLAIMS1. A engineered protein comprising a monkeypox virus (MPXV) OPG153 protein globular domain, wherein the MPXV OPG153 protein globular domain comprises or consists of an amino acid sequence at least 90% identical to amino acids 1-359 of SEQ ID NO: 1 or 2 and (i) comprises one or more substitution(s) relative to the sequence of amino acids 1-359 of SEQ ID NO: 1 or 2 and / or (ii) comprises a heterologous sequence fused to its N-terminus and / or C-terminus.

2. The engineered protein of claim 1, wherein the MPXV OPG153 protein globular domain comprises amino acids 1-366 or 1-368 of SEQ ID NO: 1 or 2, wherein the MPXV OPG153 comprises one or more substitution selected from the group consisting of: G229P, A25D, K47C / N309C, K47C / D310C, D305P, and N351E.

3. The engineered protein of claim 2, wherein the MPXV OPG153 comprises one or more substitution set selected from the group consisting of: (a) K47C / N309C, N351E, G229P, and D305P; (b) K47C / N309C, N351E, and G229P; (c) K47C / N309C, N351E, and D305P; (d) K47C / N309C, G229P. and D305P; (e) N351E, G229P, and D305P; and (f) K47C / D310C, N351E, G229P, and D305P.

4. The engineered protein of any one of claims 1-3, wherein the engineered protein comprises an N-terminal signal sequence.

5. The engineered protein of any one of claims 1-4, wherein the engineered protein comprises a transmembrane domain positioned C-terminally relative to the MPXV OPG153 protein globular domain.

6. The engineered protein of any one of claims 1-5, wherein the MPXV OPG153 protein globular domain comprises amino acids 1-360, 1-361, 1-362, 1-363, 1-364, 1-365, 1-366, 1-367, 1-368, or 1-369 of SEQ ID NO: 1 or 2.

7. The engineered protein of any one of claims 1-6, wherein the engineered protein comprises a self-assembling nanoparticle polypeptide.

8. The engineered protein of any one of claims 1-7, wherein the MPXV OPG153 protein globular domain comprises one or more of the substitutions listed in Table 1.794922-1531-8179, v.

19. The engineered protein of any one of claims 1-8, wherein position(s) 31, 32, 35-42, 87, 92, 96, 104, 105, 107-117, 124, 128, 131, 133-140, 142. 144, 145, 150, 152, 153, 156, 157, 160, 163, 164, 167, 171, 174-177, 192, 194, 196, 197, 200, 201, 203-208, 210, 211, 214, 235, 270-272, 278, 291, 293-305, 310, 317, 319, 321, 323-326, 328, 329, 332, 340-343, 349, 350, 352-355, 357, 363, and / or 364, and preferably position(s) 92, 114, 136, 150, 153, 156, 197, 201, 205, 207. 235, 300, 310, 321, 323, 343, and / or 355, of the MPXV OPG153 protein globular domain are not changed relative to the sequence of SEQ ID NO: 1 or 2.

10. A nucleic acid molecule comprising a nucleic acid sequence encoding an engineered protein comprising a monkeypox vims (MPXV) OPG153 protein globular domain, wherein the MPXV OPG153 protein globular domain comprises or consists of an amino acid sequence at least 90% identical to amino acids 1-359 of SEQ ID NO: 1 or 2 and (i) comprises one or more substitution(s) relative to the sequence of amino acids 1-359 of SEQ ID NO: 1 or 2 and / or (ii) comprises a heterologous sequence fused to its N-temrinus and / or C-terminus.

11. The nucleic acid molecule of claim 8, wherein the engineered protein encoded by the nucleic acid sequence is the engineered protein of any one of claims 2-9.

12. An immunogenic composition comprising an engineered protein comprising a monkeypox vims (MPXV) OPG153 protein globular domain and an adjuvant, wherein the MPXV OPG153 protein globular domain comprises or consists of an amino acid sequence at least 90% identical to amino acids 1-359 of SEQ ID NO: 1 or 2.

13. An immunogenic composition comprising a nucleic acid molecule comprising a nucleic acid sequence encoding an engineered protein comprising a monkeypox vims (MPXV) OPG153 protein globular domain, wherein the MPXV OPG153 protein globular domain comprises or consists of an amino acid sequence at least 90% identical to amino acids 1-359 of SEQ ID NO: 1 or 2.

14. The immunogenic composition of claim 12 or 13, wherein the MPXV OPG153 protein globular domain (i) comprises one or more substitution(s) relative to the sequence of amino acids 1-359 of SEQ ID NO: 1 or 2 and / or (ii) comprises a heterologous sequence fused to its N-terminus and / or C-terminus.804922-1531-8179, v.

115. The immunogenic composition of claim 14, wherein the engineered protein, or the engineered protein encoded by the nucleic acid sequence, is the engineered protein of any one of claims 2-9.

16. The immunogenic composition of any one of claims 13-15, wherein the nucleic acid is an mRNA.

17. The immunogenic composition of any one of claims 13-16, wherein the nucleic acid is formulated within a cationic lipid nanoparticle.

18. A method of (i) treating or preventing monkeypox virus (MPXV) infection or a disease associated with MPXV infection in a subject, (ii) eliciting an immune response in a subject, and / or (iii) reducing MPXV viral shedding in a subject, the method comprising administering to the subject an effective amount of the immunogenic composition of claim 12-17.

19. The method of claim 18, wherein the administration induces the generation of an immune response against orthopox viruses other than MPXV.

20. The method of claim 18 or 19, wherein the immunogenic composition does not comprise additional MPXV antigens.814922-1531-8179, v. 1